BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: D’Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P, Schölmerich J. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763-786. [PMID: 17258735 DOI: 10.1053/j.gastro.2006.12.038] [Cited by in Crossref: 629] [Cited by in F6Publishing: 553] [Article Influence: 41.9] [Reference Citation Analysis]
Number Citing Articles
1 Yoon JY, Cheon JH, Park JJ, Hong SP, Kim TI, Kim WH. Clinical outcomes and factors for response prediction after the first course of corticosteroid therapy in patients with active ulcerative colitis. J Gastroenterol Hepatol. 2011;26:1114-1122. [PMID: 21299620 DOI: 10.1111/j.1440-1746.2011.06688.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
2 Hanauer SB, Kirsner JB. Treat the Patient or Treat the Disease? Dig Dis 2012;30:400-3. [DOI: 10.1159/000338139] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
3 Bharadwaj S, Tandon P, Kulkarni G, Rivas J, Charles R. The role of endoscopy in inflammatory bowel disease. J Dig Dis. 2015;16:689-698. [PMID: 26595156 DOI: 10.1111/1751-2980.12301] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
4 Kerur B, Litman HJ, Stern JB, Weber S, Lightdale JR, Rufo PA, Bousvaros A. Correlation of endoscopic disease severity with pediatric ulcerative colitis activity index score in children and young adults with ulcerative colitis. World J Gastroenterol 2017; 23(18): 3322-3329 [PMID: 28566893 DOI: 10.3748/wjg.v23.i18.3322] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
5 Koutroubakis IE, Ramos-Rivers C, Regueiro M, Koutroumpakis E, Click B, Schwartz M, Swoger J, Baidoo L, Hashash JG, Barrie A. Five-Year Period Prevalence and Characteristics of Anemia in a Large US Inflammatory Bowel Disease Cohort. J Clin Gastroenterol. 2016;50:638-643. [PMID: 26485103 DOI: 10.1097/mcg.0000000000000417] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
6 Grosen A, Bungum M, Christensen LA, Cordelli E, Larsen OH, Leter G, Julsgaard M, Vestergaard T, Villani P, Hvas CL, Kelsen J. Semen Quality and Sperm DNA Integrity in Patients With Severe Active Inflammatory Bowel Disease and Effects of Tumour Necrosis Factor-alpha Inhibitors. Journal of Crohn's and Colitis 2019;13:564-71. [DOI: 10.1093/ecco-jcc/jjy198] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
7 Peyrin-Biroulet L, Bressenot A, Kampman W. Histologic remission: the ultimate therapeutic goal in ulcerative colitis? Clin Gastroenterol Hepatol. 2014;12:929-34.e2. [PMID: 23911875 DOI: 10.1016/j.cgh.2013.07.022] [Cited by in Crossref: 99] [Cited by in F6Publishing: 90] [Article Influence: 12.4] [Reference Citation Analysis]
8 Telesco SE, Brodmerkel C, Zhang H, Kim LL, Johanns J, Mazumder A, Li K, Baribaud F, Curran M, Strauss R, Paxson B, Plevy S, Davison T, Knight L, Dibben S, Schreiber S, Sandborn W, Rutgeerts P, Siegel CA, Reinisch W, Greenbaum LE. Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis. Gastroenterology 2018;155:1008-1011.e8. [PMID: 29981298 DOI: 10.1053/j.gastro.2018.06.077] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
9 Ishida N, Miyazu T, Takano R, Tamura S, Tani S, Kagami T, Yamade M, Hamaya Y, Iwaizumi M, Osawa S, Furuta T, Miyajima H, Sugimoto K. Prostaglandin E-major urinary metabolite versus fecal immunochemical occult blood test as a biomarker for patient with ulcerative colitis. BMC Gastroenterol 2020;20:114. [PMID: 32306914 DOI: 10.1186/s12876-020-01256-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
10 Bernardo S, Fernandes SR, Gonçalves AR, Valente A, Baldaia C, Santos PM, Correia LA. Predicting the Course of Disease in Hospitalized Patients With Acute Severe Ulcerative Colitis. Inflamm Bowel Dis 2019;25:541-6. [PMID: 30085135 DOI: 10.1093/ibd/izy256] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
11 Ciccocioppo R, Klersy C, Russo ML, Valli M, Boccaccio V, Imbesi V, Ardizzone S, Porro GB, Corazza GR. Validation of the Italian translation of the Inflammatory Bowel Disease Questionnaire. Dig Liver Dis. 2011;43:535-541. [PMID: 21315666 DOI: 10.1016/j.dld.2010.12.014] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
12 Fireman E, Masarwy F, Groisman G, Shtark M, Kopelman Y, Kivity S, Fireman Z. Induced sputum eosinophilia in ulcerative colitis patients: the lung as a mirror image of intestine? Respir Med 2009;103:1025-32. [PMID: 19230639 DOI: 10.1016/j.rmed.2009.01.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
13 Travis SP, Schnell D, Feagan BG, Abreu MT, Altman DG, Hanauer SB, Krzeski P, Lichtenstein GR, Marteau PR, Mary JY. The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]. J Crohns Colitis. 2015;9:607-616. [PMID: 25956538 DOI: 10.1093/ecco-jcc/jjv077] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
14 Cordes F, Lenker E, Spille LJ, Weinhage T, Bettenworth D, Kessel C, Schmidt HH, Foell D, Varga G. Tofacitinib Reprograms Human Monocytes of IBD Patients and Healthy Controls Toward a More Regulatory Phenotype. Inflamm Bowel Dis. 2020;26:391-406. [PMID: 31560043 DOI: 10.1093/ibd/izz213] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
15 Mosli MH, Feagan BG, Sandborn WJ, Dʼhaens G, Behling C, Kaplan K, Driman DK, Shackelton LM, Baker KA, Macdonald JK, Vandervoort MK, Geboes K, Levesque BG. Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices. Inflamm Bowel Dis 2014;20:564-75. [PMID: 24412993 DOI: 10.1097/01.MIB.0000437986.00190.71] [Cited by in Crossref: 73] [Cited by in F6Publishing: 22] [Article Influence: 10.4] [Reference Citation Analysis]
16 Keefer L, Kiebles JL, Martinovich Z, Cohen E, Van Denburg A, Barrett TA. Behavioral interventions may prolong remission in patients with inflammatory bowel disease. Behav Res Ther. 2011;49:145-150. [PMID: 21256475 DOI: 10.1016/j.brat.2010.12.005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
17 Armstrong D, Barkun A, Bridges R, Carter R, de Gara C, Dube C, Enns R, Hollingworth R, Macintosh D, Borgaonkar M. Canadian Association of Gastroenterology consensus guidelines on safety and quality indicators in endoscopy. Can J Gastroenterol. 2012;26:17-31. [PMID: 22308578 DOI: 10.1155/2012/173739] [Cited by in Crossref: 51] [Cited by in F6Publishing: 60] [Article Influence: 5.7] [Reference Citation Analysis]
18 Chen P, Xu H, Tang H, Zhao F, Yang C, Kwok LY, Cong C, Wu Y, Zhang W, Zhou X, Zhang H. Modulation of gut mucosal microbiota as a mechanism of probiotics-based adjunctive therapy for ulcerative colitis. Microb Biotechnol 2020;13:2032-43. [PMID: 32969200 DOI: 10.1111/1751-7915.13661] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
19 Panés J, Feagan BG, Hussain F, Levesque BG, Travis SP. Central Endoscopy Reading in Inflammatory Bowel Diseases: Table 1. ECCOJC 2016;10:S542-7. [DOI: 10.1093/ecco-jcc/jjv171] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
20 Moore AC, Huang VW, Bourdages R, Fedorak RN, Reinhard C, Leung Y, Bressler B, Rosenfeld G. IBDoc Canadian User Performance Evaluation. Inflamm Bowel Dis 2019;25:1107-14. [PMID: 30535387 DOI: 10.1093/ibd/izy357] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
21 Wang SL, Shao BZ, Zhao SB, Chang X, Wang P, Miao CY, Li ZS, Bai Y. Intestinal autophagy links psychosocial stress with gut microbiota to promote inflammatory bowel disease. Cell Death Dis 2019;10:391. [PMID: 31564717 DOI: 10.1038/s41419-019-1634-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
22 Ni X, Fan S, Zhang Y, Wang Z, Ding L, Li Y, Li J. Coordinated Hospital-Home Fecal Microbiota Transplantation via Percutaneous Endoscopic Cecostomy for Recurrent Steroid-Dependent Ulcerative Colitis. Gut Liver 2016;10:975-80. [PMID: 27282271 DOI: 10.5009/gnl15456] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
23 Theocharidou E, Gossios TD, Griva T, Giouleme O, Douma S, Athyros VG, Karagiannis A. Is there an association between inflammatory bowel diseases and carotid intima-media thickness? Preliminary data. Angiology. 2014;65:543-550. [PMID: 23748978 DOI: 10.1177/0003319713489876] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
24 Joseph NE, Weber CR. Histology and Pathology of Inflammatory Bowel Disease. In: Baumgart DC, editor. Crohn's Disease and Ulcerative Colitis. Boston: Springer US; 2012. pp. 287-306. [DOI: 10.1007/978-1-4614-0998-4_22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
25 Sandborn WJ, Hanauer S, Lichtenstein GR, Safdi M, Edeline M, Scott Harris M. Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies. Aliment Pharmacol Ther. 2011;34:747-756. [PMID: 21848857 DOI: 10.1111/j.1365-2036.2011.04800.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
26 Pagnini C, Menasci F, Festa S, Rizzatti G, Fave GD. “Mucosal healing” in ulcerative colitis: Between clinical evidence and market suggestion. World J Gastrointest Pathophysiol 2014; 5(2): 54-62 [PMID: 24891976 DOI: 10.4291/wjgp.v5.i2.54] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
27 Kornbluth A, Sachar DB;  Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501-23; quiz 524. [PMID: 20068560 DOI: 10.1038/ajg.2009.727] [Cited by in Crossref: 826] [Cited by in F6Publishing: 722] [Article Influence: 75.1] [Reference Citation Analysis]
28 Sasanuma S, Ohtsuka K, Kudo SE, Ogata N, Maeda Y, Misawa M, Mori Y, Kudo T, Hisayuki T, Wakamura K, Hayashi T, Katagiri A, Miyachi H, Baba T, Ishida F. Narrow band imaging efficiency in evaluation of mucosal healing/relapse of ulcerative colitis. Endosc Int Open 2018;6:E518-23. [PMID: 29713677 DOI: 10.1055/s-0044-102297] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
29 Ishida N, Miyazu T, Matsuura T, Takano R, Tamura S, Kagami T, Tani S, Yamade M, Hamaya Y, Iwaizumi M, Osawa S, Furuta T, Sugimoto K. Effect of ulcerative colitis duration on the usefulness of immunochemical fecal occult blood test result as a disease activity biomarker. Int J Colorectal Dis 2020;35:1729-39. [PMID: 32472230 DOI: 10.1007/s00384-020-03636-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
30 Lair-mehiri L, Stefanescu C, Vaysse T, Laharie D, Roblin X, Rosa I, Treton X, Abitbol V, Amiot A, Bouguen G, Dib N, Fumery M, Pariente B, Carbonnel F, Peyrin-biroulet L, Simon M, Viennot S, Bouhnik Y. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. Digestive and Liver Disease 2020;52:268-73. [DOI: 10.1016/j.dld.2019.10.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
31 Attauabi M, Höglund C, Fassov J, Pedersen KB, Hansen HB, Wildt S, Jensen MD, Neumann A, Lind C, Jacobsen HA, Popa AM, Kjeldsen J, Pedersen N, Molazahi A, Haderslev K, Aalykke C, Knudsen T, Cebula W, Munkholm P, Bendtsen F, Seidelin JB, Burisch J. Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases. Scand J Gastroenterol 2021;56:1040-8. [PMID: 34224299 DOI: 10.1080/00365521.2021.1946588] [Reference Citation Analysis]
32 Liu X, Yu R, Zhu L, Hou X, Zou K. Bidirectional Regulation of Circadian Disturbance and Inflammation in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017;23:1741-1751. [PMID: 28902123 DOI: 10.1097/mib.0000000000001265] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 9.3] [Reference Citation Analysis]
33 Rubio MG, Amo-Mensah K, Gray JM, Nguyen VQ, Nakat S, Grider D, Love K, Boone JH, Sorrentino D. Fecal lactoferrin accurately reflects mucosal inflammation in inflammatory bowel disease. World J Gastrointest Pathophysiol 2019; 10(5): 54-63 [PMID: 31911845 DOI: 10.4291/wjgp.v10.i5.54] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
34 Brain O, Travis SP. Therapy of ulcerative colitis: state of the art: . Current Opinion in Gastroenterology 2008;24:469-74. [DOI: 10.1097/mog.0b013e3282ff0dd5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
35 Baumgart DC, Targan SR, Dignass AU, Mayer L, van Assche G, Hommes DW, Hanauer SB, Mahadevan U, Reinisch W, Plevy SE. Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2010;16:620-629. [PMID: 19714757 DOI: 10.1002/ibd.21084] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
36 Vande Casteele N, Khanna R. Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis. Pharm Res 2017;34:1556-63. [PMID: 28374338 DOI: 10.1007/s11095-017-2150-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
37 Zhang T, Ding C, Xie T, Yang J, Dai X, Lv T, Li Y, Gu L, Wei Y, Gong J, Zhu W, Li N, Li J. Skeletal muscle depletion correlates with disease activity in ulcerative colitis and is reversed after colectomy. Clin Nutr. 2017;36:1586-1592. [PMID: 27814937 DOI: 10.1016/j.clnu.2016.10.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
38 Syversen SW, Goll GL, Jørgensen KK, Sandanger Ø, Sexton J, Olsen IC, Gehin JE, Warren DJ, Brun MK, Klaasen RA, Karlsen LN, Noraberg G, Zettel C, Ljoså MKA, Haugen AJ, Njålla RJ, Bruun TJ, Seeberg KA, Michelsen B, Strand EK, Skorpe S, Blomgren IM, Bragnes YH, Dotterud CK, Thune T, Ystrøm CM, Torp R, Mielnik P, Mørk C, Kvien TK, Jahnsen J, Bolstad N, Haavardsholm EA. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial. JAMA 2021;325:1744-54. [PMID: 33944876 DOI: 10.1001/jama.2021.4172] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
39 Celikbilek M, Dogan S, Ozbakır O, Zararsız G, Kücük H, Gürsoy S, Yurci A, Güven K, Yücesoy M. Neutrophil-lymphocyte ratio as a predictor of disease severity in ulcerative colitis. J Clin Lab Anal 2013;27:72-6. [PMID: 23292894 DOI: 10.1002/jcla.21564] [Cited by in Crossref: 113] [Cited by in F6Publishing: 104] [Article Influence: 14.1] [Reference Citation Analysis]
40 Cao Y, Zhang B, Wu Y, Wang Q, Wang J, Shen F. The Value of Fecal Microbiota Transplantation in the Treatment of Ulcerative Colitis Patients: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract 2018;2018:5480961. [PMID: 29849592 DOI: 10.1155/2018/5480961] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
41 Shin J, Kong SM, Seong G, Kim YH. What is the appropriate cut-off value of CRP to predict endoscopic remission in patients with ulcerative colitis in clinical remission? Int J Colorectal Dis 2020;35:2249-55. [PMID: 32749515 DOI: 10.1007/s00384-020-03705-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Cincin A, Sunbul M, Kivrak T, Atas H, Sari I, Tigen K, Kani T, Akin H, Imeryuz N, Basaran Y. Evaluation of Cardiac Function by Two-Dimensional Speckle Tracking Echocardiography in Ulcerative Colitis Patients. Dig Dis Sci 2014;59:3004-11. [DOI: 10.1007/s10620-014-3274-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
43 Wolvers D, Antoine JM, Myllyluoma E, Schrezenmeir J, Szajewska H, Rijkers GT. Guidance for substantiating the evidence for beneficial effects of probiotics: Prevention and management of infections by probiotics. J Nutr. 2010;140:698S-712S. [PMID: 20107143 DOI: 10.3945/jn.109.113753] [Cited by in Crossref: 101] [Cited by in F6Publishing: 88] [Article Influence: 9.2] [Reference Citation Analysis]
44 Kane S, Lu F, Kornbluth A, Awais D, Higgins PD. Controversies in mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2009;15:796-800. [PMID: 19213060 DOI: 10.1002/ibd.20875] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
45 Langhorst J, Boone J, Lauche R, Rueffer A, Dobos G. Faecal Lactoferrin, Calprotectin, PMN-elastase, CRP, and White Blood Cell Count as Indicators for Mucosal Healing and Clinical Course of Disease in Patients with Mild to Moderate Ulcerative Colitis: Post Hoc Analysis of a Prospective Clinical Trial. J Crohns Colitis 2016;10:786-94. [PMID: 26874351 DOI: 10.1093/ecco-jcc/jjw044] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
46 Dai YC, Zheng L, Zhang YL, Chen X, Chen DL, Tang ZP. Effects of Jianpi Qingchang decoction on the quality of life of patients with ulcerative colitis: A randomized controlled trial. Medicine (Baltimore). 2017;96:e6651. [PMID: 28422869 DOI: 10.1097/md.0000000000006651] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
47 Travis S, Stange E, Lémann M, Øresland T, Bemelman W, Chowers Y, Colombel J, D'haens G, Ghosh S, Marteau P, Kruis W, Mortensen N, Penninckx F, Gassull M. European evidence-based Consensus on the management of ulcerative colitis: Current management. Journal of Crohn's and Colitis 2008;2:24-62. [DOI: 10.1016/j.crohns.2007.11.002] [Cited by in Crossref: 378] [Cited by in F6Publishing: 321] [Article Influence: 29.1] [Reference Citation Analysis]
48 Zhai H, Huang W, Liu A, Li Q, Hao Q, Ma L, Yang F, Zhang S. Current smoking improves ulcerative colitis patients' disease behaviour in the northwest of China. Prz Gastroenterol 2017;12:286-90. [PMID: 29358998 DOI: 10.5114/pg.2017.72104] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
49 Lee HJ, Song HJ, Jeong JH, Kim HU, Boo SJ, Na SY. Ophthalmologic manifestations in patients with inflammatory bowel disease. Intest Res 2017;15:380-7. [PMID: 28670235 DOI: 10.5217/ir.2017.15.3.380] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
50 Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017;11:649-670. [PMID: 28158501 DOI: 10.1093/ecco-jcc/jjx008] [Cited by in Crossref: 682] [Cited by in F6Publishing: 556] [Article Influence: 227.3] [Reference Citation Analysis]
51 D'haens G, Feagan B, Colombel J, Sandborn WJ, Reinisch W, Rutgeerts P, Carbonnel F, Mary J, Danese S, Fedorak RN, Hanauer S, Lémann M. Challenges to the Design, Execution, and Analysis of Randomized Controlled Trials for Inflammatory Bowel Disease. Gastroenterology 2012;143:1461-9. [DOI: 10.1053/j.gastro.2012.09.031] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
52 Ding H, Dupont AW, Singhal S, Scott LD, Guha S, Younes M, Bi X. In vivo analysis of mucosal lipids reveals histological disease activity in ulcerative colitis using endoscope-coupled Raman spectroscopy. Biomed Opt Express 2017;8:3426-39. [PMID: 28717578 DOI: 10.1364/BOE.8.003426] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 3.3] [Reference Citation Analysis]
53 Aktaş B, Altınbaş A, Başar O, Yılmaz B, Ekiz F, Giniş Z, Oztürk G, Coban S, Tuna Y, Uçar E, Erarslan E, Yüksel O. Serum m 30 levels reflects ulcerative colitis activity. Inflamm Bowel Dis 2013;19:2400-3. [PMID: 23945185 DOI: 10.1097/MIB.0b013e3182a0ea38] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
54 Argyriou K, Samuel S, Moran GW. Acetarsol in the management of mesalazine-refractory ulcerative proctitis: a tertiary-level care experience. European Journal of Gastroenterology & Hepatology 2019;31:183-6. [DOI: 10.1097/meg.0000000000001326] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
55 Walsh AJ, Bryant RV, Travis SP. Current best practice for disease activity assessment in IBD. Nat Rev Gastroenterol Hepatol. 2016;13:567-579. [PMID: 27580684 DOI: 10.1038/nrgastro.2016.128] [Cited by in Crossref: 90] [Cited by in F6Publishing: 84] [Article Influence: 18.0] [Reference Citation Analysis]
56 Lim H, Kim HJ, Hong SJ, Kim S. Nutrient intake and bone mineral density by nutritional status in patients with inflammatory bowel disease. J Bone Metab. 2014;21:195-203. [PMID: 25247157 DOI: 10.11005/jbm.2014.21.3.195] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
57 王承党, 郭晓雄. 炎症性肠病治疗的理想目标: 深度缓解的意义和对策. 世界华人消化杂志 2015; 23(24): 3824-3830 [DOI: 10.11569/wcjd.v23.i24.3824] [Reference Citation Analysis]
58 Pedersen G, Brynskov J. Topical Rosiglitazone Treatment Improves Ulcerative Colitis by Restoring Peroxisome Proliferator-Activated Receptor-γ Activity. American Journal of Gastroenterology 2010;105:1595-603. [DOI: 10.1038/ajg.2009.749] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 4.0] [Reference Citation Analysis]
59 D'haens G, Sandborn WJ, Barrett K, Hodgson I, Streck P. Once-Daily MMX® Mesalamine for Endoscopic Maintenance of Remission of Ulcerative Colitis. American Journal of Gastroenterology 2012;107:1064-77. [DOI: 10.1038/ajg.2012.103] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
60 Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2010;16:338-346. [PMID: 19637362 DOI: 10.1002/ibd.20997] [Cited by in Crossref: 146] [Cited by in F6Publishing: 131] [Article Influence: 13.3] [Reference Citation Analysis]
61 Taghvaei T, Maleki I, Nagshvar F, Fakheri H, Hosseini V, Valizadeh SM, Neishaboori H. Fecal calprotectin and ulcerative colitis endoscopic activity index as indicators of mucosal healing in ulcerative colitis. Intern Emerg Med 2015;10:321-8. [DOI: 10.1007/s11739-014-1144-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
62 Magro F, Langner C, Driessen A, Ensari A, Geboes K, Mantzaris GJ, Villanacci V, Becheanu G, Borralho Nunes P, Cathomas G, Fries W, Jouret-Mourin A, Mescoli C, de Petris G, Rubio CA, Shepherd NA, Vieth M, Eliakim R; European Society of Pathology (ESP); European Crohn's and Colitis Organisation (ECCO). European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis. 2013;7:827-851. [PMID: 23870728 DOI: 10.1016/j.crohns.2013.06.001] [Cited by in Crossref: 336] [Cited by in F6Publishing: 263] [Article Influence: 42.0] [Reference Citation Analysis]
63 Gray JM, Knight K, Nguyen VQ, Rubio MG, Irby L, Boone JH, Sorrentino D. Fecal Lactoferrin and Other Stool Markers during Normal Pregnancy and in Inflammatory Bowel Diseases: A Prospective Study and Review of the Literature. Inflamm Intest Dis 2020;5:151-7. [PMID: 32999888 DOI: 10.1159/000508970] [Reference Citation Analysis]
64 Hauso Ø, Martinsen TC, Waldum H. 5-Aminosalicylic acid, a specific drug for ulcerative colitis. Scandinavian Journal of Gastroenterology 2015;50:933-41. [DOI: 10.3109/00365521.2015.1018937] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
65 Arkteg CB, Goll R, Gundersen MD, Anderssen E, Fenton C, Florholmen J. Mucosal gene transcription of ulcerative colitis in endoscopic remission. Scand J Gastroenterol 2020;55:139-47. [PMID: 31918598 DOI: 10.1080/00365521.2019.1710245] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
66 Coutzac C, Chapuis J, Poullenot F, Chabrun E, Capdepont M, Blanco P, Laharie D. Association Between Infliximab Trough Levels and the Occurrence of Paradoxical Manifestations in Patients with Inflammatory Bowel Disease: a Case-Control Study. J Crohns Colitis 2015;9:982-7. [PMID: 26351388 DOI: 10.1093/ecco-jcc/jjv159] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
67 Brahmania M, Bernstein CN. Physician global assessments or blood tests do not predict mucosal healing in ulcerative colitis. Can J Gastroenterol Hepatol 2014;28:325-9. [PMID: 24945187 DOI: 10.1155/2014/737349] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
68 Martinez-Fierro ML, Garza-Veloz I, Rocha-Pizaña MR, Cardenas-Vargas E, Cid-Baez MA, Trejo-Vazquez F, Flores-Morales V, Villela-Ramirez GA, Delgado-Enciso I, Rodriguez-Sanchez IP, Ortiz-Castro Y. Serum cytokine, chemokine, and growth factor profiles and their modulation in inflammatory bowel disease. Medicine (Baltimore) 2019;98:e17208. [PMID: 31567972 DOI: 10.1097/MD.0000000000017208] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 6.5] [Reference Citation Analysis]
69 Kolehmainen S, Ylisaukko-Oja T, Jokelainen J, Koivusalo M, Jokiranta TS, Sipponen T. Benefit of measuring vedolizumab concentrations in inflammatory bowel disease patients in a real-world setting. Scand J Gastroenterol 2021;56:906-13. [PMID: 34154506 DOI: 10.1080/00365521.2021.1938206] [Reference Citation Analysis]
70 Nuij V, Fuhler GM, Edel AJ, Ouwendijk RJ, Rijk MC, Beukers R, Quispel R, van Tilburg AJ, Tang TJ, Smalbraak H, Bruin KF, Lindenburg F, Peyrin-Biroulet L, van der Woude CJ; Dutch Delta IBD Group. Benefit of Earlier Anti-TNF Treatment on IBD Disease Complications? J Crohns Colitis 2015;9:997-1003. [PMID: 26223842 DOI: 10.1093/ecco-jcc/jjv130] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
71 American Society for Gastrointestinal Endoscopy Standards of Practice Committee. , Shergill AK, Lightdale JR, Bruining DH, Acosta RD, Chandrasekhara V, Chathadi KV, Decker GA, Early DS, Evans JA, Fanelli RD, Fisher DA, Fonkalsrud L, Foley K, Hwang JH, Jue TL, Khashab MA, Muthusamy VR, Pasha SF, Saltzman JR, Sharaf R, Cash BD, DeWitt JM. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc 2015; 81: 1101-21. e1-13. [PMID: 25800660 DOI: 10.1016/j.gie.2014.10.030] [Cited by in Crossref: 172] [Cited by in F6Publishing: 150] [Article Influence: 28.7] [Reference Citation Analysis]
72 Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM, Zeitz J, Rogler G, Schoepfer AM. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106:110-119. [PMID: 20808297 DOI: 10.1038/ajg.2010.343] [Cited by in Crossref: 265] [Cited by in F6Publishing: 219] [Article Influence: 24.1] [Reference Citation Analysis]
73 Addis J, Mohammed N, Rotimi O, Magee D, Jha A, Subramanian V. Raman spectroscopy of endoscopic colonic biopsies from patients with ulcerative colitis to identify mucosal inflammation and healing. Biomed Opt Express. 2016;7:2022-2035. [PMID: 27231640 DOI: 10.1364/boe.7.002022] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
74 Mitsuishi T. Correlation between histological findings and endoscopic findings in patients with ulcerative colitis: Basal plasmacytosis is an important finding suggesting active inflammation. JGH Open 2019;3:100-4. [PMID: 31061883 DOI: 10.1002/jgh3.12111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
75 Sandborn WJ, Colombel JF, Sands BE, Rutgeerts P, Targan SR, Panaccione R, Bressler B, Geboes K, Schreiber S, Aranda R. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology. 2012;143:62-69.e4. [PMID: 22504093 DOI: 10.1053/j.gastro.2012.04.010] [Cited by in Crossref: 89] [Cited by in F6Publishing: 88] [Article Influence: 9.9] [Reference Citation Analysis]
76 Paschos P, Katsoula A, Salanti G, Giouleme O, Athanasiadou E, Tsapas A. Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life. Aliment Pharmacol Ther. 2018;48:1174-1185. [PMID: 30378141 DOI: 10.1111/apt.15005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
77 Guida L, Di Giorgio FM, Busacca A, Carrozza L, Ciminnisi S, Almasio PL, Di Marco V, Cappello M. Perception of the Role of Food and Dietary Modifications in Patients with Inflammatory Bowel Disease: Impact on Lifestyle. Nutrients 2021;13:759. [PMID: 33652848 DOI: 10.3390/nu13030759] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Dobric S, Popovic D, Nikolic M, Andrejevic S, Spuran M, Bonaci-nikolic B. Anti-neutrophil cytoplasmic antibodies (ANCA) specific for one or several antigens: useful markers for subtypes of ulcerative colitis and associated primary sclerosing cholangitis. Clinical Chemistry and Laboratory Medicine 2012;50. [DOI: 10.1515/cclm.2011.797] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
79 Oliva S, Di Nardo G, Ferrari F, Mallardo S, Rossi P, Patrizi G, Cucchiara S, Stronati L. Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther. 2012;35:327-334. [PMID: 22150569 DOI: 10.1111/j.1365-2036.2011.04939.x] [Cited by in Crossref: 134] [Cited by in F6Publishing: 119] [Article Influence: 13.4] [Reference Citation Analysis]
80 Panés J, Alfaro I. New treatment strategies for ulcerative colitis. Expert Rev Clin Immunol 2017;13:963-73. [PMID: 28617055 DOI: 10.1080/1744666X.2017.1343668] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
81 Walsh A, Palmer R, Travis S. Mucosal Healing As a Target of Therapy for Colonic Inflammatory Bowel Disease and Methods to Score Disease Activity. Gastrointestinal Endoscopy Clinics of North America 2014;24:367-78. [DOI: 10.1016/j.giec.2014.03.005] [Cited by in Crossref: 69] [Cited by in F6Publishing: 59] [Article Influence: 9.9] [Reference Citation Analysis]
82 Long Y, Zhao X, Xia C, Liu X, Fan C, Liu C. Infection of Epstein-Barr Virus is Associated with the Decrease of Helios+FoxP3+Regulatory T Cells in Active Ulcerative Colitis Patients. Immunol Invest 2021;50:23-36. [PMID: 32046542 DOI: 10.1080/08820139.2020.1723021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
83 Sun H, Vesely R, Taminiau J, Szitanyi P, Papadopoulos EJ, Isaac M, Klein A, Uzu S, Griebel D, Mulberg AE; International Inflammatory Bowel Disease Working Group. Steps toward harmonization for clinical development of medicines in pediatric ulcerative colitis-a global scientific discussion, part 1: efficacy endpoints and disease outcome assessments. J Pediatr Gastroenterol Nutr 2014;58:679-83. [PMID: 24866781 DOI: 10.1097/MPG.0000000000000306] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
84 Zhou JQ, Zeng L, Zhang Q, Wu XY, Zhang ML, Jing XT, Wang YF, Gan HT. Clinical features of Epstein-Barr virus in the intestinal mucosa and blood of patients with inflammatory bowel disease. Saudi J Gastroenterol 2020. [PMID: 33078719 DOI: 10.4103/sjg.SJG_30_20] [Reference Citation Analysis]
85 Berrill JW, Sadlier M, Hood K, Green JT. Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. J Crohns Colitis. 2014;8:945-955. [PMID: 24529603 DOI: 10.1016/j.crohns.2014.01.018] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 8.4] [Reference Citation Analysis]
86 Pearl DS, Shah K, Whittaker MA, Nitch-Smith H, Brown JF, Shute JK, Trebble TM. Cytokine mucosal expression in ulcerative colitis, the relationship between cytokine release and disease activity. J Crohns Colitis. 2013;7:481-489. [PMID: 22974822 DOI: 10.1016/j.crohns.2012.07.022] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
87 Bollegala N, Brill H, Marshall JK. Resource utilization during pediatric to adult transfer of care in IBD. Journal of Crohn's and Colitis 2013;7:e55-60. [DOI: 10.1016/j.crohns.2012.05.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
88 Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660-1666. [PMID: 18623174 DOI: 10.1002/ibd.20520] [Cited by in Crossref: 395] [Cited by in F6Publishing: 366] [Article Influence: 32.9] [Reference Citation Analysis]
89 Novacek G, Weltermann A, Sobala A, Tilg H, Petritsch W, Reinisch W, Mayer A, Haas T, Kaser A, Feichtenschlager T, Fuchssteiner H, Knoflach P, Vogelsang H, Miehsler W, Platzer R, Tillinger W, Jaritz B, Schmid A, Blaha B, Dejaco C, Eichinger S. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology. 2010;139:779-787, 787.e1. [PMID: 20546736 DOI: 10.1053/j.gastro.2010.05.026] [Cited by in Crossref: 153] [Cited by in F6Publishing: 127] [Article Influence: 13.9] [Reference Citation Analysis]
90 Wilhelm SM, McKenney KA, Rivait KN, Kale-Pradhan PB. A review of infliximab use in ulcerative colitis. Clin Ther. 2008;30:223-230. [PMID: 18343261 DOI: 10.1016/j.clinthera.2008.02.014] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
91 Sandborn WJ, Regula J, Feagan BG, Belousova E, Jojic N, Lukas M, Yacyshyn B, Krzeski P, Yeh CH, Messer CA, Hanauer SB. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology 2009; 137: 1934-43. e1-3. [PMID: 19766640 DOI: 10.1053/j.gastro.2009.08.069] [Cited by in Crossref: 105] [Cited by in F6Publishing: 93] [Article Influence: 8.8] [Reference Citation Analysis]
92 Turner D, Hyams J, Markowitz J, Lerer T, Mack DR, Evans J, Pfefferkorn M, Rosh J, Kay M, Crandall W, Keljo D, Otley AR, Kugathasan S, Carvalho R, Oliva-hemker M, Langton C, Mamula P, Bousvaros A, Leleiko N, Griffiths AM. Appraisal of the pediatric ulcerative colitis activity index (PUCAI): . Inflammatory Bowel Diseases 2009;15:1218-23. [DOI: 10.1002/ibd.20867] [Cited by in Crossref: 152] [Cited by in F6Publishing: 137] [Article Influence: 12.7] [Reference Citation Analysis]
93 Hirai F, Matsui T. A critical review of endoscopic indices in ulcerative colitis: inter-observer variation of the endoscopic index. Clin J Gastroenterol 2008;1:40-5. [PMID: 26193460 DOI: 10.1007/s12328-008-0018-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
94 Yarlas A, D'Haens G, Willian MK, Teynor M. Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study. Inflamm Bowel Dis. 2018;24:450-463. [PMID: 29361097 DOI: 10.1093/ibd/izx041] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
95 Chen XL, Deng J, Chen X, Wan SS, Wang Y, Cao Q. High incidence and morbidity of Clostridium difficile infection among hospitalized patients with inflammatory bowel disease: A prospective observational cohort study. J Dig Dis 2019;20:460-6. [DOI: 10.1111/1751-2980.12798] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
96 Patil DT, Moss AC, Odze RD. Role of Histologic Inflammation in the Natural History of Ulcerative Colitis. Gastrointest Endosc Clin N Am 2016;26:629-40. [PMID: 27633592 DOI: 10.1016/j.giec.2016.06.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
97 Vaughn BP, Shah S, Cheifetz AS. The role of mucosal healing in the treatment of patients with inflammatory bowel disease. Curr Treat Options Gastroenterol 2014;12:103-17. [PMID: 24395615 DOI: 10.1007/s11938-013-0008-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
98 Ditisheim S, Fournier N, Juillerat P, Pittet V, Michetti P, Gabay C, Finckh A. Inflammatory Articular Disease in Patients with Inflammatory Bowel Disease: Result of the Swiss IBD Cohort Study. Inflammatory Bowel Diseases 2015;21:2598-604. [DOI: 10.1097/mib.0000000000000548] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
99 Alrubaiy L, Dodds P, Hutchings HA, Russell IT, Watkins A, Williams JG. Development and validation of a new disease severity index: the Inflammatory Bowel Disease Index (IBDEX). Frontline Gastroenterol 2015;6:161-8. [PMID: 28839806 DOI: 10.1136/flgastro-2014-100530] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
100 Pineton de Chambrun G, Peyrin-biroulet L, Lémann M, Colombel J. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010;7:15-29. [DOI: 10.1038/nrgastro.2009.203] [Cited by in Crossref: 301] [Cited by in F6Publishing: 275] [Article Influence: 25.1] [Reference Citation Analysis]
101 Bessissow T, Lemmens B, Ferrante M, Bisschops R, Van Steen K, Geboes K, Van Assche G, Vermeire S, Rutgeerts P, De Hertogh G. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. Am J Gastroenterol. 2012;107:1684-1692. [PMID: 23147523 DOI: 10.1038/ajg.2012.301] [Cited by in Crossref: 171] [Cited by in F6Publishing: 149] [Article Influence: 19.0] [Reference Citation Analysis]
102 Patel A, Panchal H, Dubinsky MC. Fecal Calprotectin Levels Predict Histological Healing in Ulcerative Colitis: . Inflammatory Bowel Diseases 2017;23:1600-4. [DOI: 10.1097/mib.0000000000001157] [Cited by in Crossref: 38] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
103 Sagawa T, Kakizaki S, Tomizawa T, Nakayama T, Tanaka H, Tojima H, Sato K, Kusano M, Okamura S, Yamada M. Faecal lactoferrin is a useful biomarker for mucosal healing in patients with ulcerative colitis during granulocyte and monocyte adsorptive apheresis therapy. Colorectal Dis 2016;18:696-702. [PMID: 26748553 DOI: 10.1111/codi.13258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
104 Shen Y, Shi L, Zhang J, Zhu H, Yao Y, Liu Z, Zou X, Zhang X. Thromboelastography in Patients with Inflammatory Bowel Disease. Gastroenterol Res Pract 2020;2020:3245657. [PMID: 32565780 DOI: 10.1155/2020/3245657] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
105 Yarlas A, Rubin DT, Panés J, Lindsay JO, Vermeire S, Bayliss M, Cappelleri JC, Maher S, Bushmakin AG, Chen LA, Dibonaventura M. Burden of Ulcerative Colitis on Functioning and Well-being: A Systematic Literature Review of the SF-36® Health Survey. Journal of Crohn's and Colitis 2018;12:600-9. [DOI: 10.1093/ecco-jcc/jjy024] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
106 Cordes F, Demmig C, Bokemeyer A, Brückner M, Lenze F, Lenz P, Nowacki T, Tepasse P, Schmidt HH, Schmidt MA, Cichon C, Bettenworth D. MicroRNA-320a Monitors Intestinal Disease Activity in Patients With Inflammatory Bowel Disease.Clin Transl Gastroenterol. 2020;11:e00134. [PMID: 32352717 DOI: 10.14309/ctg.0000000000000134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
107 van den Brink G, Stapersma L, Vlug LE, Rizopolous D, Bodelier AG, van Wering H, Hurkmans PCWM, Stuyt RJL, Hendriks DM, van der Burg JAT, Utens EMWJ, Escher JC. Clinical disease activity is associated with anxiety and depressive symptoms in adolescents and young adults with inflammatory bowel disease. Aliment Pharmacol Ther 2018;48:358-69. [PMID: 29897134 DOI: 10.1111/apt.14832] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
108 Dulai PS, Levesque BG, Feagan BG, D'Haens G, Sandborn WJ. Assessment of mucosal healing in inflammatory bowel disease: review. Gastrointest Endosc 2015;82:246-55. [PMID: 26005012 DOI: 10.1016/j.gie.2015.03.1974] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 6.8] [Reference Citation Analysis]
109 Sipponen T, Turunen U, Lautenschlager I, Nieminen U, Arola J, Halme L. Human herpesvirus 6 and cytomegalovirus in ileocolonic mucosa in inflammatory bowel disease. Scand J Gastroenterol. 2011;46:1324-1333. [PMID: 21879802 DOI: 10.3109/00365521.2011.605466] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
110 Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, d'Haens G, d'Hoore A, Mantzanaris G, Novacek G, Öresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, van Assche G. [Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management (Spanish version)]. Rev Gastroenterol Mex 2015;80:32-73. [PMID: 25769217 DOI: 10.1016/j.rgmx.2014.10.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
111 Linton L, Karlsson M, Grundström J, Hjalmarsson E, Lindberg A, Lindh E, Glise H, Befrits R, Janczewska I, Karlén P, Winqvist O, Eberhardson M. HLA-DR(hi) and CCR9 Define a Pro-Inflammatory Monocyte Subset in IBD. Clin Transl Gastroenterol 2012;3:e29. [PMID: 23254312 DOI: 10.1038/ctg.2012.23] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
112 Baumgart DC, Thomas S, Przesdzing I, Metzke D, Bielecki C, Lehmann SM, Lehnardt S, Dörffel Y, Sturm A, Scheffold A. Exaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel disease. Clin Exp Immunol. 2009;157:423-436. [PMID: 19664152 DOI: 10.1111/j.1365-2249.2009.03981.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 4.8] [Reference Citation Analysis]
113 Ayling RM, Kok K. Fecal Calprotectin. Elsevier; 2018. pp. 161-90. [DOI: 10.1016/bs.acc.2018.07.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 12.3] [Reference Citation Analysis]
114 Sachar DB. Management of acute, severe ulcerative colitis: Management of severe ulcerative colitis. Journal of Digestive Diseases 2012;13:65-8. [DOI: 10.1111/j.1751-2980.2011.00560.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
115 Hafeez R, Punwani S, Pendse D, Boulos P, Bloom S, Halligan S, Taylor SA. Derivation of a T2-weighted MRI total colonic inflammation score (TCIS) for assessment of patients with severe acute inflammatory colitis-a preliminary study. Eur Radiol 2011;21:366-77. [PMID: 20803202 DOI: 10.1007/s00330-010-1934-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
116 Ma C, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, Siegel CA, Peyrin-biroulet L, D’haens G, Sandborn WJ, Feagan BG, Jairath V. Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. Clinical Gastroenterology and Hepatology 2018;16:637-647.e13. [DOI: 10.1016/j.cgh.2017.08.025] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 9.7] [Reference Citation Analysis]
117 Trivedi I, Hanauer SB. Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases. Expert Opin Drug Saf 2015;14:1915-34. [PMID: 26559664 DOI: 10.1517/14740338.2015.1108961] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
118 Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, Sandborn WJ, Feagan BG. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2015;110:802-19; quiz 820. [PMID: 25964225 DOI: 10.1038/ajg.2015.120] [Cited by in Crossref: 275] [Cited by in F6Publishing: 233] [Article Influence: 45.8] [Reference Citation Analysis]
119 Ananthakrishnan AN, McGinley EL, Binion DG, Saeian K. Simple score to identify colectomy risk in ulcerative colitis hospitalizations. Inflamm Bowel Dis. 2010;16:1532-1540. [PMID: 20091926 DOI: 10.1002/ibd.21225] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
120 Masclee GM, Penders J, Jonkers DM, Wolffs PF, Pierik MJ. Is clostridium difficile associated with relapse of inflammatory bowel disease? results from a retrospective and prospective cohort study in the Netherlands. Inflamm Bowel Dis. 2013;19:2125-2131. [PMID: 23867869 DOI: 10.1097/mib.0b013e318297d222] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 3.1] [Reference Citation Analysis]
121 Puolanne A, Kolho K, Alfthan H, Ristimäki A, Mustonen H, Färkkilä M. Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease. Dig Dis Sci 2017;62:3123-30. [DOI: 10.1007/s10620-017-4770-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
122 Herfarth H, Barnes EL, Valentine JF, Hanson J, Higgins PDR, Isaacs KL, Jackson S, Osterman MT, Anton K, Ivanova A, Long MD, Martin C, Sandler RS, Abraham B, Cross RK, Dryden G, Fischer M, Harlan W, Levy C, McCabe R, Polyak S, Saha S, Williams E, Yajnik V, Serrano J, Sands BE, Lewis JD; Clinical Research Alliance of the Crohn’s and Colitis Foundation. Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis. Gastroenterology 2018;155:1098-1108.e9. [PMID: 29964043 DOI: 10.1053/j.gastro.2018.06.046] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 11.7] [Reference Citation Analysis]
123 Stojkovic Lalosevic M, Toncev L, Stankovic S, Dragasevic S, Stojkovic S, Jovicic I, Stulic M, Culafic D, Milovanovic T, Stojanovic M, Aleksic M, Stjepanovic M, Lalosevic J, Kiurski S, Oluic B, Pavlovic Markovic A, Stojkovic M. Hepcidin Is a Reliable Marker of Iron Deficiency Anemia in Newly Diagnosed Patients with Inflammatory Bowel Disease. Dis Markers 2020;2020:8523205. [PMID: 33354248 DOI: 10.1155/2020/8523205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Bertani L, Blandizzi C, Mumolo MG, Ceccarelli L, Albano E, Tapete G, Baiano Svizzero G, Zanzi F, Coppini F, de Bortoli N, Bellini M, Morganti R, Marchi S, Costa F. Fecal Calprotectin Predicts Mucosal Healing in Patients With Ulcerative Colitis Treated With Biological Therapies: A Prospective Study. Clin Transl Gastroenterol 2020;11:e00174. [PMID: 32677804 DOI: 10.14309/ctg.0000000000000174] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
125 Turner D, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue K, Walters TD, Zachos M, Mamula P, Beaton DE, Steinhart AH, Griffiths AM. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007;133:423-32. [PMID: 17681163 DOI: 10.1053/j.gastro.2007.05.029] [Cited by in Crossref: 603] [Cited by in F6Publishing: 539] [Article Influence: 43.1] [Reference Citation Analysis]
126 Peyrin-Biroulet L, Bouhnik Y, Roblin X, Bonnaud G, Hagège H, Hébuterne X. French national consensus clinical guidelines for the management of ulcerative colitis. Dig Liver Dis. 2016;48:726-733. [PMID: 27158125 DOI: 10.1016/j.dld.2016.03.029] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
127 Tontini GE, Bisschops R, Neumann H. Endoscopic scoring systems for inflammatory bowel disease: pros and cons. Expert Rev Gastroenterol Hepatol. 2014;8:543-554. [PMID: 24650249 DOI: 10.1586/17474124.2014.899899] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
128 Reeve R, Gottlieb K. Sequentially Determined Measures of Interobserver Agreement (Kappa) in Clinical Trials May Vary Independent of Changes in Observer Performance. Drug Inf J 2019. [DOI: 10.1177/2168479019874059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
129 Calvet X, Esplugues JV. ¿Cómo comparar fármacos biológicos? Reumatología Clínica 2014;10:353-9. [DOI: 10.1016/j.reuma.2014.06.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
130 Gui X, Li J, Ueno A, Iacucci M, Qian J, Ghosh S. Histopathological Features of Inflammatory Bowel Disease are Associated With Different CD4+ T Cell Subsets in Colonic Mucosal Lamina Propria. J Crohns Colitis 2018;12:1448-58. [PMID: 30137280 DOI: 10.1093/ecco-jcc/jjy116] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
131 Park S, Abdi T, Gentry M, Laine L. Histological Disease Activity as a Predictor of Clinical Relapse Among Patients With Ulcerative Colitis: Systematic Review and Meta-Analysis. Am J Gastroenterol. 2016;111:1692-1701. [PMID: 27725645 DOI: 10.1038/ajg.2016.418] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 15.4] [Reference Citation Analysis]
132 Topal F, Camyar H, Saritas Yuksel E, Gunay S, Topal F, Gür EÖ. Work Productivity Loss in Inflammatory Bowel Disease Patients in Turkey. Gastroenterol Res Pract 2020;2020:6979720. [PMID: 32382271 DOI: 10.1155/2020/6979720] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
133 Lewis JD, Lichtenstein GR, Deren JJ, Sands BE, Hanauer SB, Katz JA, Lashner B, Present DH, Chuai S, Ellenberg JH. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology. 2008;134:688-695. [PMID: 18325386 DOI: 10.1053/j.gastro.2007.12.012] [Cited by in Crossref: 145] [Cited by in F6Publishing: 145] [Article Influence: 10.4] [Reference Citation Analysis]
134 Theocharidou E, Tellis CC, Mavroudi M, Soufleris K, Gossios TD, Giouleme O, Athyros VG, Tselepis AD, Karagiannis A. Lipoprotein-associated phospholipase A2 and arterial stiffness evaluation in patients with inflammatory bowel diseases. J Crohns Colitis. 2014;8:936-944. [PMID: 24529818 DOI: 10.1016/j.crohns.2014.01.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
135 Yamamoto-Furusho JK, Martínez-Benítez B, Sánchez-Morales GE. Histopathologic Parameters at Diagnosis as Early Predictors of Histologic Remission along the Course of Ulcerative Colitis. Gastroenterol Res Pract 2020;2020:8891937. [PMID: 33343656 DOI: 10.1155/2020/8891937] [Reference Citation Analysis]
136 James SL, Christophersen CT, Bird AR, Conlon MA, Rosella O, Gibson PR, Muir JG. Abnormal fibre usage in UC in remission. Gut 2015;64:562-70. [DOI: 10.1136/gutjnl-2014-307198] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 7.1] [Reference Citation Analysis]
137 Witges K, Sexton K, Graff LA, Targownik LE, Lix LM, Haviva C, Stone J, Shafer LA, Vagianos K, Bernstein CN. What Is a Flare? The Manitoba Living With IBD Study. Inflamm Bowel Dis 2021:izab192. [PMID: 34347048 DOI: 10.1093/ibd/izab192] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
138 Crothers JW, Chu ND, Nguyen LTT, Phillips M, Collins C, Fortner K, Del Rio-Guerra R, Lavoie B, Callas P, Velez M, Cohn A, Elliott RJ, Wong WF, Vo E, Wilcox R, Smith M, Kassam Z, Budd R, Alm EJ, Mawe GM, Moses PL. Daily, oral FMT for long-term maintenance therapy in ulcerative colitis: results of a single-center, prospective, randomized pilot study. BMC Gastroenterol 2021;21:281. [PMID: 34238227 DOI: 10.1186/s12876-021-01856-9] [Reference Citation Analysis]
139 Atreya R, Neurath MF. Current and Future Targets for Mucosal Healing in Inflammatory Bowel Disease. Visc Med. 2017;33:82-88. [PMID: 28612022 DOI: 10.1159/000458006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
140 Bryant RV, Winer S, Travis SP, Riddell RH. Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? J Crohns Colitis. 2014;8:1582-1597. [PMID: 25267173 DOI: 10.1016/j.crohns.2014.08.011] [Cited by in Crossref: 162] [Cited by in F6Publishing: 142] [Article Influence: 23.1] [Reference Citation Analysis]
141 Cano-martínez D, Román ID, T. Lobo MV, Pastor O, Moreno-villena I, Paradela A, Hernández-breijo B, Fernández-moreno MD, Monserrat J, Sanmartín-salinas P, Gisbert JP, Guijarro LG. Effect of Infliximab in oxidised serum albumin levels during experimental colitis. Biomarkers 2014;19:693-701. [DOI: 10.3109/1354750x.2014.982189] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
142 Mohammed Vashist N, Samaan M, Mosli MH, Parker CE, MacDonald JK, Nelson SA, Zou GY, Feagan BG, Khanna R, Jairath V. Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis. Cochrane Database Syst Rev 2018;1:CD011450. [PMID: 29338066 DOI: 10.1002/14651858.CD011450.pub2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
143 Harris MS, Hartman D, Lemos BR, Erlich EC, Spence S, Kennedy S, Ptak T, Pruitt R, Vermeire S, Fox BS. AVX-470, an Orally Delivered Anti-Tumour Necrosis Factor Antibody for Treatment of Active Ulcerative Colitis: Results of a First-in-Human Trial. ECCOJC 2016;10:631-40. [DOI: 10.1093/ecco-jcc/jjw036] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 7.8] [Reference Citation Analysis]
144 Yarlas A, Bayliss M, Cappelleri JC, Maher S, Bushmakin AG, Chen LA, Manuchehri A, Healey P. Psychometric validation of the SF-36® Health Survey in ulcerative colitis: results from a systematic literature review. Qual Life Res 2018;27:273-90. [DOI: 10.1007/s11136-017-1690-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
145 Rismo R, Olsen T, Cui G, Christiansen I, Florholmen J, Goll R. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis. Scand J Gastroenterol. 2012;47:538-547. [PMID: 22486187 DOI: 10.3109/00365521.2012.667146] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
146 Jiang XL, Wang HH, Cui HF. Combined diosmectite and mesalazine treatment for mild-to-moderate ulcerative colitis: a randomized, placebo-controlled study. Med Sci Monit 2015;21:163-70. [PMID: 25582578 DOI: 10.12659/MSM.891400] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
147 Saigusa K, Matsuoka K, Sugimoto S, Arai M, Kiyohara H, Takeshita K, Mizuno S, Mori K, Nanki K, Takeshita T, Nakazato Y, Yajima T, Naganuma M, Hisamatsu T, Ogata H, Iwao Y, Kanai T. Ulcerative colitis endoscopic index of severity is associated with long‐term prognosis in ulcerative colitis patients treated with infliximab. Digestive Endoscopy 2016;28:665-70. [DOI: 10.1111/den.12655] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
148 Tandon P, Leung K, Yusuf A, Huang VW. Noninvasive Methods For Assessing Inflammatory Bowel Disease Activity in Pregnancy: A Systematic Review. Journal of Clinical Gastroenterology 2019;53:574-81. [DOI: 10.1097/mcg.0000000000001244] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 7.5] [Reference Citation Analysis]
149 Tyler CJ, Guzman M, Lundborg LR, Yeasmin S, Perez-Jeldres T, Yarur A, Behm B, Dulai PS, Patel D, Bamias G, Rivera-Nieves J. Inherent Immune Cell Variation Within Colonic Segments Presents Challenges for Clinical Trial Design. J Crohns Colitis 2020;14:1364-77. [PMID: 32239151 DOI: 10.1093/ecco-jcc/jjaa067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
150 Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641-1657. [PMID: 17499606 DOI: 10.1016/s0140-6736(07)60751-x] [Cited by in Crossref: 1121] [Cited by in F6Publishing: 482] [Article Influence: 80.1] [Reference Citation Analysis]
151 Browne AS, Kelly CR. Fecal Transplant in Inflammatory Bowel Disease. Gastroenterol Clin North Am 2017;46:825-37. [PMID: 29173524 DOI: 10.1016/j.gtc.2017.08.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
152 Lan D, Niu J, Miao J, Dong X, Wang H, Yang G, Wang K, Miao Y. Expression of guanylate cyclase-C, guanylin, and uroguanylin is downregulated proportionally to the ulcerative colitis disease activity index. Sci Rep. 2016;6:25034. [PMID: 27125248 DOI: 10.1038/srep25034] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
153 Selvaggi F, Pellino G, Ghezzi G, Corona D, Riegler G, Delaini GG. A think tank of the Italian Society of Colorectal Surgery (SICCR) on the surgical treatment of inflammatory bowel disease using the Delphi method: ulcerative colitis. Tech Coloproctol 2015;19:627-38. [PMID: 26386867 DOI: 10.1007/s10151-015-1367-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
154 Gomollón F, García-López S, Sicilia B, Gisbert JP, Hinojosa J; en representació del Grupo Espa˜nol de Trabajode Enfermedad de Crohn y Colitis Ulcerosa or Spanish Group for Working on Crohn’sDisease and Ulcerative Colitis (GETECCU). [Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU]. Gastroenterol Hepatol 2013;36:e1-47. [PMID: 24215088 DOI: 10.1016/j.gastrohep.2012.11.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
155 Fornaro R, Caratto M, Barbruni G, Fornaro F, Salerno A, Giovinazzo D, Sticchi C, Caratto E. Surgical and medical treatment in patients with acute severe ulcerative colitis. J Dig Dis. 2015;16:558-567. [PMID: 26315728 DOI: 10.1111/1751-2980.12278] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
156 Baudet A, Colombel J, Cortot A, Dupas J, Brazier F, Savoye G, Lerebours E, Justum A, Reimund J. A fulminant colitis index greater or equal to 8 is not predictive of colectomy risk in infliximab-treated moderate-to-severe ulcerative colitis attacks. Gastroentérologie Clinique et Biologique 2010;34:612-7. [DOI: 10.1016/j.gcb.2010.07.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
157 Guardiola J, Lobatón T, Rodríguez-Alonso L, Ruiz-Cerulla A, Arajol C, Loayza C, Sanjuan X, Sánchez E, Rodríguez-Moranta F. Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission. Clin Gastroenterol Hepatol. 2014;12:1865-1870. [PMID: 24993368 DOI: 10.1016/j.cgh.2014.06.020] [Cited by in Crossref: 91] [Cited by in F6Publishing: 83] [Article Influence: 13.0] [Reference Citation Analysis]
158 Vatn MH, Sandvik AK. Inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2015;50:748-62. [DOI: 10.3109/00365521.2015.1033000] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
159 Iskandar HN, Ciorba MA. Biomarkers in inflammatory bowel disease: current practices and recent advances. Transl Res. 2012;159:313-325. [PMID: 22424434 DOI: 10.1016/j.trsl.2012.01.001] [Cited by in Crossref: 116] [Cited by in F6Publishing: 104] [Article Influence: 12.9] [Reference Citation Analysis]
160 Bennebroek Evertsz' F, Nieuwkerk PT, Stokkers PC, Ponsioen CY, Bockting CL, Sanderman R, Sprangers MA. The Patient Simple Clinical Colitis Activity Index (P-SCCAI) can detect ulcerative colitis (UC) disease activity in remission: A comparison of the P-SCCAI with clinician-based SCCAI and biological markers. Journal of Crohn's and Colitis 2013;7:890-900. [DOI: 10.1016/j.crohns.2012.11.007] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 6.5] [Reference Citation Analysis]
161 Lang A, Salomon N, Wu JC, Kopylov U, Lahat A, Har-Noy O, Ching JY, Cheong PK, Avidan B, Gamus D. Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2015;13:1444-9.e1. [PMID: 25724700 DOI: 10.1016/j.cgh.2015.02.019] [Cited by in Crossref: 166] [Cited by in F6Publishing: 138] [Article Influence: 27.7] [Reference Citation Analysis]
162 Lukas M, Drastich P, Konecny M, Gionchetti P, Urban O, Cantoni F, Bortlik M, Duricova D, Bulitta M. Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis. Inflamm Bowel Dis. 2010;16:1180-1186. [PMID: 19885903 DOI: 10.1002/ibd.21161] [Cited by in Crossref: 67] [Cited by in F6Publishing: 70] [Article Influence: 6.1] [Reference Citation Analysis]
163 Ishida N, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Real-World Efficacy and Safety Monitoring for Predicting Continuation of Tofacitinib Therapy in Patients with Ulcerative Colitis. Dig Dis Sci 2021. [PMID: 34460029 DOI: 10.1007/s10620-021-07233-6] [Reference Citation Analysis]
164 Ishida N, Higuchi T, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis. Sci Rep 2021;11:12431. [PMID: 34127687 DOI: 10.1038/s41598-021-90558-z] [Reference Citation Analysis]
165 Johnsen KM, Goll R, Hansen V, Olsen T, Rismo R, Heitmann R, Gundersen MD, Kvamme JM, Paulssen EJ, Kileng H, Johnsen K, Florholmen J. Repeated intensified infliximab induction - results from an 11-year prospective study of ulcerative colitis using a novel treatment algorithm. Eur J Gastroenterol Hepatol 2017;29:98-104. [PMID: 27749779 DOI: 10.1097/MEG.0000000000000753] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
166 Grill M, Högenauer C, Blesl A, Haybaeck J, Golob-Schwarzl N, Ferreirós N, Thomas D, Gurke R, Trötzmüller M, Köfeler HC, Gallé B, Schicho R. Members of the endocannabinoid system are distinctly regulated in inflammatory bowel disease and colorectal cancer. Sci Rep 2019;9:2358. [PMID: 30787385 DOI: 10.1038/s41598-019-38865-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 13.5] [Reference Citation Analysis]
167 Timmer A, Sutherland LR. Epidemiology of Digestive Diseases. In: Ahrens W, Pigeot I, editors. Handbook of Epidemiology. New York: Springer; 2014. pp. 2355-88. [DOI: 10.1007/978-0-387-09834-0_49] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
168 Musa S, Thomson S, Cowan M, Rahman T. Clostridium difficile infection and inflammatory bowel disease. Scand J Gastroenterol. 2010;45:261-272. [PMID: 20025557 DOI: 10.3109/00365520903497098] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
169 Iwańczak B, Ruczka M, Matusiewicz M, Pytrus T, Matusiewicz K, Krzesiek E. Correlation between biomarkers (calprotectin, seromucoid, metalloproteinase-3 and CRP) and clinical and endoscopic activity of ulcerative colitis in children. Adv Med Sci 2020;65:259-64. [PMID: 32361483 DOI: 10.1016/j.advms.2020.03.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
170 Yan B, Feagan B, Teriaky A, Mosli M, Mohamed R, Williams G, Yeung E, Yong E, Haig A, Sey M, Stitt L, Zou GY, Jairath V. Reliability of EUS indices to detect inflammation in ulcerative colitis. Gastrointest Endosc 2017;86:1079-87. [PMID: 28760533 DOI: 10.1016/j.gie.2017.07.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
171 Grammatikopoulou MG, Gkiouras K, Theodoridis X, Asteriou E, Forbes A, Bogdanos DP. Oral Adjuvant Curcumin Therapy for Attaining Clinical Remission in Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients 2018;10:E1737. [PMID: 30424514 DOI: 10.3390/nu10111737] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
172 Hahn L, Beggs A, Wahaib K, Kodali L, Kirkwood V. Vedolizumab: An integrin-receptor antagonist for treatment of Crohn's disease and ulcerative colitis. Am J Health Syst Pharm 2015;72:1271-8. [PMID: 26195652 DOI: 10.2146/ajhp140449] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
173 Salem MS, Melmed GY. The Role of Histology in Determining Disease Activity, Treatment, and Prognosis: Are We There yet? Gastrointest Endosc Clin N Am 2019;29:437-46. [PMID: 31078246 DOI: 10.1016/j.giec.2019.02.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
174 Tedjo DI, Jonkers DM, Savelkoul PH, Masclee AA, van Best N, Pierik MJ, Penders J. The effect of sampling and storage on the fecal microbiota composition in healthy and diseased subjects. PLoS One. 2015;10:e0126685. [PMID: 26024217 DOI: 10.1371/journal.pone.0126685] [Cited by in Crossref: 100] [Cited by in F6Publishing: 92] [Article Influence: 16.7] [Reference Citation Analysis]
175 Jonefjäll B, Strid H, Ohman L, Svedlund J, Bergstedt A, Simren M. Characterization of IBS-like symptoms in patients with ulcerative colitis in clinical remission. Neurogastroenterol Motil. 2013;25:756-e578. [PMID: 23731196 DOI: 10.1111/nmo.12163] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 6.0] [Reference Citation Analysis]
176 Turner D, Seow CH, Greenberg GR, Griffiths AM, Silverberg MS, Steinhart AH. A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7:1081-1088. [PMID: 19577010 DOI: 10.1016/j.cgh.2009.06.024] [Cited by in Crossref: 109] [Cited by in F6Publishing: 99] [Article Influence: 9.1] [Reference Citation Analysis]
177 Marín-jiménez I, Nos P, Domènech E, Riestra S, Gisbert JP, Calvet X, Cortés X, Iglesias E, Huguet JM, Taxonera C, Fernández R, Carpio D, Gutiérrez A, Guardiola J, Laria LC, Sicilia B, Bujanda L, Cea-calvo L, Romero C, Rincón Ó, Juliá B, Panés J. Diagnostic Performance of the Simple Clinical Colitis Activity Index Self-Administered Online at Home by Patients With Ulcerative Colitis: CRONICA-UC Study. American Journal of Gastroenterology 2016;111:261-8. [DOI: 10.1038/ajg.2015.403] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 6.4] [Reference Citation Analysis]
178 Connolly MP, Nielsen SK, Currie CJ, Marteau P, Probert CS, Travis SP. An economic evaluation comparing concomitant oral and topical mesalazine versus oral mesalazine alone in mild-to-moderately active ulcerative colitis based on results from randomised controlled trial. Journal of Crohn's and Colitis 2009;3:168-74. [DOI: 10.1016/j.crohns.2009.02.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
179 McDermott E, Keegan D, Byrne K, Doherty GA, Mulcahy HE. The Short Health Scale: a valid and reliable measure of health related quality of life in English speaking inflammatory bowel disease patients. J Crohns Colitis. 2013;7:616-621. [PMID: 22921528 DOI: 10.1016/j.crohns.2012.07.030] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
180 Rath T, Billmeier U, Ferrazzi F, Vieth M, Ekici A, Neurath MF, Atreya R. Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases. Front Immunol 2018;9:1700. [PMID: 30131801 DOI: 10.3389/fimmu.2018.01700] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
181 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
182 Cai J, Chen H, Weng M, Jiang S, Gao J. Diagnostic and Clinical Significance of Serum Levels of D-Lactate and Diamine Oxidase in Patients with Crohn's Disease. Gastroenterol Res Pract 2019;2019:8536952. [PMID: 31531016 DOI: 10.1155/2019/8536952] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
183 Eberhardson M, Marits P, Jones M, Jones P, Karlen P, Karlsson M, Cotton G, Woznica K, Maltman B, Glise H, Winqvist O. Treatment of inflammatory bowel disease by chemokine receptor-targeted leukapheresis. Clin Immunol 2013;149:73-82. [PMID: 23892544 DOI: 10.1016/j.clim.2013.05.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
184 Palone F, Vitali R, Cucchiara S, Pierdomenico M, Negroni A, Aloi M, Nuti F, Felice C, Armuzzi A, Stronati L. Role of HMGB1 as a suitable biomarker of subclinical intestinal inflammation and mucosal healing in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:1448-1457. [PMID: 24983978 DOI: 10.1097/mib.0000000000000113] [Cited by in Crossref: 42] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
185 Vachon A, Scott FI. The treatment approach to inflammatory bowel disease in 2020. Curr Opin Gastroenterol 2020;36:247-56. [PMID: 32452863 DOI: 10.1097/MOG.0000000000000653] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
186 Hindryckx P, Baert F, Hart A, Magro F, Armuzzi A, Peyrin-biroulet L; the Clinical Trial Committee Clincom of the European Crohn’s and Colitis Organisation (ECCO). Clinical Trials in Ulcerative Colitis: A Historical Perspective. ECCOJC 2015;9:580-8. [DOI: 10.1093/ecco-jcc/jjv074] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
187 Cichoż-Lach H, Michalak A, Kopertowska-Majchrzak M, Eder P, Stawczyk-Eder K, Waszak K, Talar-Wojnarowska R, Zatorski H, Solarska-Półchłopek A, Chmielnicki J, Filip R, Pękala A, Janiak M, Skrobot K, Kasińska E, Krogulecki M, Królikowski P, Kłopocka M, Liebert A, Poniewierka E, Smoła I, Gąsiorowska A, Kaczka A, Wypych J, Wojciechowski K, Drygała S, Zagórowicz E. Characteristics of patients with moderate-to-severe ulcerative colitis treated with vedolizumab: results from a Polish multicenter, prospective, observational real-life study (the POLONEZ study). Therap Adv Gastroenterol 2021;14:17562848211036456. [PMID: 34484422 DOI: 10.1177/17562848211036456] [Reference Citation Analysis]
188 Kanazawa M, Takahashi F, Tominaga K, Abe K, Izawa N, Fukushi K, Nagashima K, Kanamori A, Takenaka K, Sugaya T, Iijima M, Takada A, Imai Y, Hiraishi H, Irisawa A. Relationship between endoscopic mucosal healing and histologic inflammation during remission maintenance phase in ulcerative colitis: a retrospective study. Endosc Int Open 2019;7:E568-75. [PMID: 30957007 DOI: 10.1055/a-0869-7619] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
189 Masoodi M, Pearl DS, Eiden M, Shute JK, Brown JF, Calder PC, Trebble TM. Altered colonic mucosal Polyunsaturated Fatty Acid (PUFA) derived lipid mediators in ulcerative colitis: new insight into relationship with disease activity and pathophysiology. PLoS One 2013;8:e76532. [PMID: 24204637 DOI: 10.1371/journal.pone.0076532] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
190 Farrell D, Savage E. Symptom burden: a forgotten area of measurement in inflammatory bowel disease. Int J Nurs Pract 2012;18:497-500. [PMID: 23009379 DOI: 10.1111/j.1440-172X.2012.02063.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
191 高净, 江学良. 低剂量英夫利昔单抗不同给药次数治疗激素抵抗型溃疡性结肠炎. 世界华人消化杂志 2013; 21(15): 1453-1457 [DOI: 10.11569/wcjd.v21.i15.1453] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
192 Chen X, Hou J, Yuan Y, Huang C, Liu T, Mo C, Li H, Chen B, Xu Q, Hou Z, He W, Liu F. Adalimumab for Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta-Analysis. BioDrugs 2016;30:207-17. [PMID: 27120055 DOI: 10.1007/s40259-016-0173-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
193 Kurzepa J, Mądro A, Czechowska G, Kurzepa J, Celiński K, Kazmierak W, Slomka M. Role of MMP-2 and MMP-9 and their natural inhibitors in liver fibrosis, chronic pancreatitis and non-specific inflammatory bowel diseases. Hepatobiliary Pancreat Dis Int 2014;13:570-9. [PMID: 25475858 DOI: 10.1016/s1499-3872(14)60261-7] [Cited by in Crossref: 39] [Cited by in F6Publishing: 18] [Article Influence: 7.8] [Reference Citation Analysis]
194 Weisel K, Scott N, Berger S, Wang S, Brown K, Powell M, Broer M, Watts C, Tompson DJ, Burriss SW, Hawkins S, Abbott-Banner K, Tak PP. A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis. BMJ Open Gastroenterol 2021;8:e000680. [PMID: 34389633 DOI: 10.1136/bmjgast-2021-000680] [Reference Citation Analysis]
195 Caviezel D, Maissen S, Niess JH, Kiss C, Hruz P. High Prevalence of Vitamin D Deficiency among Patients with Inflammatory Bowel Disease. Inflamm Intest Dis 2018;2:200-10. [PMID: 30221147 DOI: 10.1159/000489010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
196 Cordes F, Laumeyer T, Gerß J, Brückner M, Lenze F, Nowacki T, Rijcken E, Tepasse P, Schmidt H, Kucharzik T, Bettenworth D. Distinct Disease Phenotype of Ulcerative Colitis in Patients With Coincident Primary Sclerosing Cholangitis: Evidence From a Large Retrospective Study With Matched Cohorts. Diseases of the Colon & Rectum 2019;62:1494-504. [DOI: 10.1097/dcr.0000000000001496] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
197 Iskandar HN, Dhere T, Farraye FA. Ulcerative Colitis: Update on Medical Management. Curr Gastroenterol Rep. 2015;17:44. [PMID: 26386686 DOI: 10.1007/s11894-015-0466-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
198 Zheng S, Yang W, Wu C, Sun L, Lin D, Lin X, Jiang L, Ding R, Jiang Y. Association of ulcerative colitis with transcobalamin II gene polymorphisms and serum homocysteine, vitamin B12, and folate levels in Chinese patients. Immunogenetics 2017;69:421-8. [DOI: 10.1007/s00251-017-0998-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
199 Wolff S, Terheggen G, Mueller R, Greinwald R, Franklin J, Kruis W. Are Endoscopic Endpoints Reliable in Therapeutic Trials of Ulcerative Colitis?: . Inflammatory Bowel Diseases 2013;19:2611-5. [DOI: 10.1097/01.mib.0000437044.43961.00] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
200 Molander P, Färkkilä M, Ristimäki A, Salminen K, Kemppainen H, Blomster T, Koskela R, Jussila A, Rautiainen H, Nissinen M, Haapamäki J, Arkkila P, Nieminen U, Kuisma J, Punkkinen J, Kolho K, Mustonen H, Sipponen T. Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission? Journal of Crohn's and Colitis 2014. [DOI: 10.1016/j.crohns.2014.06.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 38] [Article Influence: 2.1] [Reference Citation Analysis]
201 Toychiev A, Navruzov B, Pazylova D, Davis N, Badalova N, Osipova S. Intestinal protozoa and helminths in ulcerative colitis and the influence of anti-parasitic therapy on the course of the disease. Acta Trop 2021;213:105755. [PMID: 33188747 DOI: 10.1016/j.actatropica.2020.105755] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
202 Ishida N, Onoue S, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Further research on the clinical relevance of the ulcerative colitis colonoscopic index of severity for predicting 5-year relapse. Int J Colorectal Dis 2021. [PMID: 34409500 DOI: 10.1007/s00384-021-04009-2] [Reference Citation Analysis]
203 Lawrance IC, Baird A, Lightower D, Radford-smith G, Andrews JM, Connor S. Efficacy of Rectal Tacrolimus for Induction Therapy in Patients With Resistant Ulcerative Proctitis. Clinical Gastroenterology and Hepatology 2017;15:1248-55. [DOI: 10.1016/j.cgh.2017.02.027] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
204 Guerrero-alba R, Valdez-morales EE, Jimenez-vargas NN, Lopez-lopez C, Jaramillo-polanco J, Okamoto T, Nasser Y, Bunnett NW, Lomax AE, Vanner SJ. Stress activates pronociceptive endogenous opioid signalling in DRG neurons during chronic colitis. Gut 2017;66:2121-31. [DOI: 10.1136/gutjnl-2016-311456] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
205 Akpinar MY, Ozin YO, Kaplan M, Ates I, Kalkan IH, Kilic ZMY, Yuksel M, Kayacetin E. Platelet-to-lymphocyte Ratio and Neutrophil-to-lymphocyte Ratio Predict Mucosal Disease Severity in Ulcerative Colitis. J Med Biochem. 2018;37:155-162. [PMID: 30581352 DOI: 10.1515/jomb-2017-0050] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
206 Jiang XL, Cui HF, Gao J, Fan H. Low-dose Infliximab for Induction and Maintenance Treatment in Chinese Patients With Moderate to Severe Active Ulcerative Colitis. J Clin Gastroenterol 2015;49:582-8. [PMID: 25844841 DOI: 10.1097/MCG.0000000000000319] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 5.6] [Reference Citation Analysis]
207 Gasia MF, Ghosh S, Panaccione R, Ferraz JG, Kaplan GG, Leung Y, Novak KL, Seow CH, Iacucci M. Targeted Biopsies Identify Larger Proportions of Patients With Colonic Neoplasia Undergoing High-Definition Colonoscopy, Dye Chromoendoscopy, or Electronic Virtual Chromoendoscopy. Clin Gastroenterol Hepatol. 2016;14:704-12.e4. [PMID: 26804384 DOI: 10.1016/j.cgh.2015.12.047] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 7.6] [Reference Citation Analysis]
208 Levesque BG, Sandborn WJ, Ruel J, Feagan BG, Sands BE, Colombel JF. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology. 2015; 148:37-51.e1. [PMID: 25127678 DOI: 10.1053/j.gastro.2014.08.003] [Cited by in Crossref: 142] [Cited by in F6Publishing: 122] [Article Influence: 20.3] [Reference Citation Analysis]
209 Baumgart DC, Macdonald JK, Feagan B. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst Rev. 2008;CD007216. [PMID: 18646177 DOI: 10.1002/14651858.cd007216] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
210 Paine ER. Colonoscopic evaluation in ulcerative colitis. Gastroenterol Rep (Oxf). 2014;2:161-168. [PMID: 24879406 DOI: 10.1093/gastro/gou028] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
211 Hirai F, Matsui T, Aoyagi K, Inoue N, Hibi T, Oshitani N, Fujii H, Kobayashi K, Suzuki Y, Tanaka S. Validity of activity indices in ulcerative colitis: comparison of clinical and endoscopic indices. Dig Endosc. 2010;22:39-44. [PMID: 20078663 DOI: 10.1111/j.1443-1661.2009.00916.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
212 Obraztsov IV, Shirokikh KE, Obraztsova OI, Shapina MV, Wang MH, Khalif IL. Multiple Cytokine Profiling: A New Model to Predict Response to Tumor Necrosis Factor Antagonists in Ulcerative Colitis Patients. Inflamm Bowel Dis 2019;25:524-31. [PMID: 30544140 DOI: 10.1093/ibd/izy358] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
213 Nardone OM, Cannatelli R, Zardo D, Ghosh S, Iacucci M. Can advanced endoscopic techniques for assessment of mucosal inflammation and healing approximate histology in inflammatory bowel disease? Therap Adv Gastroenterol 2019;12:1756284819863015. [PMID: 31360224 DOI: 10.1177/1756284819863015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
214 Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, D'Haens G, D'Hoore A, Mantzaris G, Novacek G, Oresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6:991-1030. [PMID: 23040451 DOI: 10.1016/j.crohns.2012.09.002] [Cited by in Crossref: 657] [Cited by in F6Publishing: 567] [Article Influence: 73.0] [Reference Citation Analysis]
215 Pabla BS, Schwartz DA. Assessing Severity of Disease in Patients with Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:671-88. [PMID: 33121688 DOI: 10.1016/j.gtc.2020.08.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
216 Solberg IC, Høivik ML, Cvancarova M, Moum B. Risk matrix model for prediction of colectomy in a population-based study of ulcerative colitis patients (the IBSEN study). Scand J Gastroenterol. 2015;50:1456-1462. [PMID: 26139389 DOI: 10.3109/00365521.2015.1064991] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
217 Treton X, Laharie D. Prise en charge d’une colite aiguë grave. Gastroentérologie Clinique et Biologique 2008;32:1030-7. [DOI: 10.1016/j.gcb.2008.10.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
218 Adedokun OJ, Xu Z, Marano C, O’brien C, Szapary P, Zhang H, Johanns J, Leong RW, Hisamatsu T, Van Assche G, Danese S, Abreu MT, Sands BE, Sandborn WJ. Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2020;18:2244-2255.e9. [DOI: 10.1016/j.cgh.2019.11.059] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 19.0] [Reference Citation Analysis]
219 Guo D, Liu X, Zeng C, Cheng L, Song G, Hou X, Zhu L, Zou K. Estrogen receptor β activation ameliorates DSS-induced chronic colitis by inhibiting inflammation and promoting Treg differentiation. Int Immunopharmacol 2019;77:105971. [PMID: 31678865 DOI: 10.1016/j.intimp.2019.105971] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
220 Mitselos IV, Christodoulou DK, Katsanos KH, Tsianos EV. Role of wireless capsule endoscopy in the follow-up of inflammatory bowel disease. World J Gastrointest Endosc 2015; 7(6): 643-651 [PMID: 26078832 DOI: 10.4253/wjge.v7.i6.643] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
221 Ozawa T, Ishihara S, Fujishiro M, Saito H, Kumagai Y, Shichijo S, Aoyama K, Tada T. Novel computer-assisted diagnosis system for endoscopic disease activity in patients with ulcerative colitis. Gastrointest Endosc 2019; 89: 416-421. e1. [PMID: 30367878 DOI: 10.1016/j.gie.2018.10.020] [Cited by in Crossref: 60] [Cited by in F6Publishing: 45] [Article Influence: 20.0] [Reference Citation Analysis]
222 Yoon JY, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Correlations of C-reactive protein levels and erythrocyte sedimentation rates with endoscopic activity indices in patients with ulcerative colitis. Dig Dis Sci 2014;59:829-37. [PMID: 24352705 DOI: 10.1007/s10620-013-2907-3] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
223 Matthes H, Krummenerl T, Giensch M, Wolff C, Schulze J. Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med. 2010;10:13. [PMID: 20398311 DOI: 10.1186/1472-6882-10-13] [Cited by in Crossref: 114] [Cited by in F6Publishing: 100] [Article Influence: 10.4] [Reference Citation Analysis]
224 Holubar SD, Lightner AL, Poylin V, Vogel JD, Gaertner W, Davis B, Davis KG, Mahadevan U, Shah SA, Kane SV, Steele SR, Paquette IM, Feingold DL; Prepared on behalf of the Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Ulcerative Colitis. Dis Colon Rectum 2021;64:783-804. [PMID: 33853087 DOI: 10.1097/DCR.0000000000002037] [Reference Citation Analysis]
225 Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, Ziade N, Hashash JG. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019;65:100851. [PMID: 30837080 DOI: 10.1016/j.disamonth.2019.02.004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 25.0] [Reference Citation Analysis]
226 Boal Carvalho P, Cotter J. Mucosal Healing in Ulcerative Colitis: A Comprehensive Review. Drugs. 2017;77:159-173. [PMID: 28078646 DOI: 10.1007/s40265-016-0676-y] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 9.8] [Reference Citation Analysis]
227 Hoivik ML, Moum B, Solberg IC, Cvancarova M, Hoie O, Vatn MH, Bernklev T; IBSEN Study Group. Health-related quality of life in patients with ulcerative colitis after a 10-year disease course: results from the IBSEN study. Inflamm Bowel Dis 2012;18:1540-9. [PMID: 21936030 DOI: 10.1002/ibd.21863] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 5.5] [Reference Citation Analysis]
228 Adedokun OJ, Xu Z, Marano CW, Strauss R, Zhang H, Johanns J, Zhou H, Davis HM, Reinisch W, Feagan BG. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies. J Crohns Colitis. 2017;11:35-46. [PMID: 27440869 DOI: 10.1093/ecco-jcc/jjw133] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 13.6] [Reference Citation Analysis]
229 Iacucci M, Daperno M, Lazarev M, Arsenascu R, Tontini GE, Akinola O, Gui XS, Villanacci V, Goetz M, Lowerison M, Lethebe BC, Vecchi M, Neumann H, Ghosh S, Bisschops R, Kiesslich R. Development and reliability of the new endoscopic virtual chromoendoscopy score: the PICaSSO (Paddington International Virtual ChromoendoScopy ScOre) in ulcerative colitis. Gastrointestinal Endoscopy 2017;86:1118-1127.e5. [DOI: 10.1016/j.gie.2017.03.012] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 7.5] [Reference Citation Analysis]
230 Park SK, Ko BM, Goong HJ, Seo JY, Lee SH, Baek HL, Lee MS, Park DI. Short health scale: A valid measure of health-related quality of life in Korean-speaking patients with inflammatory bowel disease. World J Gastroenterol 2017; 23(19): 3530-3537 [PMID: 28596689 DOI: 10.3748/wjg.v23.i19.3530] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
231 Chebli LA, Chaves LD, Pimentel FF, Guerra DM, Barros RM, Gaburri PD, Zanini A, Chebli JM. Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis. Inflamm Bowel Dis. 2010;16:613-619. [PMID: 19705415 DOI: 10.1002/ibd.21083] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 4.5] [Reference Citation Analysis]
232 Pang Y, Ruan H, Wu D, Lang Y, Sun K, Xu C. Assessment of clinical activity and severity using serum ANCA and ASCA antibodies in patients with ulcerative colitis. Allergy Asthma Clin Immunol 2020;16:37. [PMID: 32477415 DOI: 10.1186/s13223-020-00433-1] [Reference Citation Analysis]
233 Lopetuso LR, Corbi M, Scaldaferri F, Petito V, Graziani C, Castri F, Neri M, Gasbarrini A, Sgambato A, Papa A. Characterization of mucosal cytokine profile in ulcerative colitis patients under conventional and anti-TNF-a treatment. Eur J Gastroenterol Hepatol 2020;32:1527-32. [PMID: 32976192 DOI: 10.1097/MEG.0000000000001933] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
234 Sandborn WJ, Panés J, Zhang H, Yu D, Niezychowski W, Su C. Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial. Gastroenterology 2016;150:96-102. [PMID: 26376350 DOI: 10.1053/j.gastro.2015.09.001] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 10.3] [Reference Citation Analysis]
235 Bewtra M, Brensinger CM, Tomov VT, Hoang TB, Sokach CE, Siegel CA, Lewis JD. An optimized patient-reported ulcerative colitis disease activity measure derived from the Mayo score and the simple clinical colitis activity index. Inflamm Bowel Dis. 2014;20:1070-1078. [PMID: 24810138 DOI: 10.1097/mib.0000000000000053] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
236 Cooney RM, Warren BF, Altman DG, Abreu MT, Travis SP. Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation. Trials 2007;8:17. [PMID: 17592647 DOI: 10.1186/1745-6215-8-17] [Cited by in Crossref: 80] [Cited by in F6Publishing: 80] [Article Influence: 5.7] [Reference Citation Analysis]
237 Olsen T, Rismo R, Gundersen MD, Paulssen EJ, Johnsen K, Kvamme JM, Goll R, Florholmen J. Normalization of mucosal tumor necrosis factor-α: A new criterion for discontinuing infliximab therapy in ulcerative colitis. Cytokine 2016;79:90-5. [PMID: 26775117 DOI: 10.1016/j.cyto.2015.12.021] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
238 Kale-pradhan PB, Pradhan RS, Wilhelm SM. Multi-Matrix System Mesalamine: To Use or Not To Use. Ann Pharmacother 2008;42:265-9. [DOI: 10.1345/aph.1k469] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
239 Freeman HJ. Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab. Ther Clin Risk Manag. 2013;9:451-456. [PMID: 24235838 DOI: 10.2147/TCRM.S38852] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
240 Armuzzi A, Van Assche G, Reinisch W, de Chambrun GP, Griffiths A, Sladek M, Preiss JC, Lukas M, D'haens G. Results of the 2nd scientific workshop of the ECCO (IV): Therapeutic strategies to enhance intestinal healing in inflammatory bowel disease. Journal of Crohn's and Colitis 2012;6:492-502. [DOI: 10.1016/j.crohns.2011.12.016] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
241 Ananthakrishnan AN, Issa M, Beaulieu DB, Skaros S, Knox JF, Lemke K, Emmons J, Lundeen SH, Otterson MF, Binion DG. History of medical hospitalization predicts future need for colectomy in patients with ulcerative colitis. Inflamm Bowel Dis. 2009;15:176-181. [PMID: 18680197 DOI: 10.1002/ibd.20639] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 4.4] [Reference Citation Analysis]
242 Dumitrescu G, Mihai C, Dranga M, Prelipcean CC. Serum 25-hydroxyvitamin D concentration and inflammatory bowel disease characteristics in Romania. World J Gastroenterol 2014; 20(9): 2392-2396 [PMID: 24605037 DOI: 10.3748/wjg.v20.i9.2392] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
243 Armuzzi A, Pugliese D, Nardone OM, Guidi L. Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab. Drug Des Devel Ther. 2013;7:289-296. [PMID: 23630414 DOI: 10.2147/dddt.s33197] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
244 Rasmussen B, Haastrup P, Wehberg S, Kjeldsen J, Waldorff FB. Predictors of health-related quality of life in patients with moderate to severely active ulcerative colitis receiving biological therapy. Scand J Gastroenterol 2020;55:656-63. [PMID: 32442051 DOI: 10.1080/00365521.2020.1768282] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
245 Tamboli CP. Current Medical Therapy for Chronic Inflammatory Bowel Diseases. Surgical Clinics of North America 2007;87:697-725. [DOI: 10.1016/j.suc.2007.03.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
246 Gupta A, Yu A, Peyrin-Biroulet L, Ananthakrishnan AN. Treat to Target: The Role of Histologic Healing in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2020;. [PMID: 33010406 DOI: 10.1016/j.cgh.2020.09.046] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
247 Corte CJ, Leong RW. Improving the utility of colonoscopy: Recent advances in practice. J Gastroenterol Hepatol. 2016;31:32-44. [PMID: 26211821 DOI: 10.1111/jgh.13056] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
248 Mukherjee A, Hazra A, Smith MK, Martin SW, Mould DR, Su C, Niezychowski W. Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial. Br J Clin Pharmacol 2018;84:1136-45. [PMID: 29377257 DOI: 10.1111/bcp.13523] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
249 Ji Y, Li X, Zhu Y, Li N, Zhang N, Niu M. Faecal microRNA as a biomarker of the activity and prognosis of inflammatory bowel diseases. Biochem Biophys Res Commun 2018;503:2443-50. [PMID: 29969632 DOI: 10.1016/j.bbrc.2018.06.174] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
250 Gustavsson A, Halfvarson J, Magnuson A, Sandberg-Gertzén H, Tysk C, Järnerot G. Long-term colectomy rate after intensive intravenous corticosteroid therapy for ulcerative colitis prior to the immunosuppressive treatment era. Am J Gastroenterol 2007;102:2513-9. [PMID: 17680849 DOI: 10.1111/j.1572-0241.2007.01435.x] [Cited by in F6Publishing: 46] [Reference Citation Analysis]
251 Gibson DJ, Ward MG, Rentsch C, Friedman AB, Taylor KM, Sparrow MP, Gibson PR. Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2020;51:612-28. [DOI: 10.1111/apt.15643] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 16.0] [Reference Citation Analysis]
252 Pai RK, Geboes K. Disease activity and mucosal healing in inflammatory bowel disease: a new role for histopathology? Virchows Arch. 2018;472:99-110. [PMID: 28555281 DOI: 10.1007/s00428-017-2156-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
253 Zezos P, Kabakchiev B, Weizman AV, Nguyen GC, Narula N, Croitoru K, Steinhart AH, Silverberg MS. Ulcerative Colitis Patients Continue to Improve Over the First Six Months of Vedolizumab Treatment: 12-Month Clinical and Mucosal Healing Effectiveness. J Can Assoc Gastroenterol 2020;3:74-82. [PMID: 32328546 DOI: 10.1093/jcag/gwy065] [Reference Citation Analysis]
254 Bryant RV, Costello SP, Schoeman S, Sathananthan D, Knight E, Lau SY, Schoeman MN, Mountifield R, Tee D, Travis SPL, Andrews JM. Limited uptake of ulcerative colitis "treat-to-target" recommendations in real-world practice. J Gastroenterol Hepatol. 2018;33:599-607. [PMID: 28806471 DOI: 10.1111/jgh.13923] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
255 Stange EF, Travis SP, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, Feakins R, Fléjou JF, Herfarth H, Hommes DW. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis. 2008;2:1-23. [PMID: 21172194 DOI: 10.1016/j.crohns.2007.11.001] [Cited by in Crossref: 353] [Cited by in F6Publishing: 324] [Article Influence: 27.2] [Reference Citation Analysis]
256 Flamant M, Paul S, Roblin X. Golimumab for the treatment of ulcerative colitis. Expert Opin Biol Ther 2017;17:879-86. [PMID: 28472597 DOI: 10.1080/14712598.2017.1327576] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
257 Sturm A, Maaser C, Calabrese E, Annese V, Fiorino G, Kucharzik T, Vavricka SR, Verstockt B, van Rheenen P, Tolan D, Taylor SA, Rimola J, Rieder F, Limdi JK, Laghi A, Krustiņš E, Kotze PG, Kopylov U, Katsanos K, Halligan S, Gordon H, González Lama Y, Ellul P, Eliakim R, Castiglione F, Burisch J, Borralho Nunes P, Bettenworth D, Baumgart DC, Stoker J; European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. J Crohns Colitis 2019;13:273-84. [PMID: 30137278 DOI: 10.1093/ecco-jcc/jjy114] [Cited by in Crossref: 92] [Cited by in F6Publishing: 74] [Article Influence: 46.0] [Reference Citation Analysis]
258 Morita Y, Bamba S, Takahashi K, Imaeda H, Nishida A, Inatomi O, Sasaki M, Tsujikawa T, Sugimoto M, Andoh A. Prediction of clinical and endoscopic responses to anti-tumor necrosis factor-α antibodies in ulcerative colitis. Scand J Gastroenterol 2016;51:934-41. [PMID: 26888161 DOI: 10.3109/00365521.2016.1144781] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
259 Alrubaiy L, Rikaby I, Sageer M, Hutchings HA, Williams JG. Systematic Review of the Clinical Disease Severity Indices for Inflammatory Bowel Disease. Inflamm Bowel Dis 2015;21:2460-6. [PMID: 25966838 DOI: 10.1097/MIB.0000000000000438] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
260 Buchner AM, Lichtenstein GR. How to Assess and Document Endoscopies in IBD Patients by Including Standard Scoring Systems. Inflamm Bowel Dis 2016;22:1010-9. [PMID: 26963565 DOI: 10.1097/MIB.0000000000000649] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
261 Minacapelli CD, Bajpai M, Geng X, Van Gurp J, Poplin E, Amenta PS, Brant SR, Das KM. miR-206 as a Biomarker for Response to Mesalamine Treatment in Ulcerative Colitis. Inflamm Bowel Dis 2019;25:78-84. [PMID: 30204869 DOI: 10.1093/ibd/izy279] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
262 Peyrin-biroulet L, Panés J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, Colombel J, Hanauer SB, Rycroft B. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clinical Gastroenterology and Hepatology 2016;14:348-354.e17. [DOI: 10.1016/j.cgh.2015.06.001] [Cited by in Crossref: 186] [Cited by in F6Publishing: 165] [Article Influence: 37.2] [Reference Citation Analysis]
263 Meucci G, Fasoli R, Saibeni S, Valpiani D, Gullotta R, Colombo E, D’Incà R, Terpin M, Lombardi G. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study. Inflamm Bowel Dis. 2012;18:1006-1010. [PMID: 21830282 DOI: 10.1002/ibd.21838] [Cited by in Crossref: 80] [Cited by in F6Publishing: 77] [Article Influence: 8.0] [Reference Citation Analysis]
264 Kawashima K, Ishihara S, Yuki T, Fukuba N, Oshima N, Kazumori H, Sonoyama H, Yamashita N, Tada Y, Kusunoki R, Oka A, Mishima Y, Moriyama I, Kinoshita Y. Fecal calprotectin level correlated with both endoscopic severity and disease extent in ulcerative colitis. BMC Gastroenterol 2016;16:47. [PMID: 27071448 DOI: 10.1186/s12876-016-0462-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
265 van den Brink G, Stapersma L, Bom AS, Rizopolous D, van der Woude CJ, Stuyt RJL, Hendriks DM, van der Burg JAT, Beukers R, Korpershoek TA, Theuns-Valks SDM, Utens EMWJ, Escher JC. Effect of Cognitive Behavioral Therapy on Clinical Disease Course in Adolescents and Young Adults With Inflammatory Bowel Disease and Subclinical Anxiety and/or Depression: Results of a Randomized Trial. Inflamm Bowel Dis 2019;25:1945-56. [PMID: 31050763 DOI: 10.1093/ibd/izz073] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
266 Li CQ, Xie XJ, Yu T, Gu XM, Zuo XL, Zhou CJ, Huang WQ, Chen H, Li YQ. Classification of inflammation activity in ulcerative colitis by confocal laser endomicroscopy. Am J Gastroenterol. 2010;105:1391-1396. [PMID: 19935787 DOI: 10.1038/ajg.2009.664] [Cited by in Crossref: 97] [Cited by in F6Publishing: 93] [Article Influence: 8.1] [Reference Citation Analysis]
267 Lopez-sanroman A. The Concept of Mucosal Healing in Ulcerative Colitis: Time and Reasons for a Reappraisal. ECCOJC 2015;10:3-4. [DOI: 10.1093/ecco-jcc/jjv183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
268 Thomas S, Metzke D, Schmitz J, Dörffel Y, Baumgart DC. Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitis. Am J Physiol Gastrointest Liver Physiol 2011;301:G1083-92. [PMID: 21903765 DOI: 10.1152/ajpgi.00217.2011] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
269 Joyce JC, Waljee AK, Khan T, Wren PA, Dave M, Zimmermann EM, Wang S, Zhu J, Higgins PD. Identification of symptom domains in ulcerative colitis that occur frequently during flares and are responsive to changes in disease activity. Health Qual Life Outcomes 2008;6:69. [PMID: 18803870 DOI: 10.1186/1477-7525-6-69] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
270 Boye B, Lundin KE, Jantschek G, Leganger S, Mokleby K, Tangen T, Jantschek I, Pripp AH, Wojniusz S, Dahlstroem A. INSPIRE study: does stress management improve the course of inflammatory bowel disease and disease-specific quality of life in distressed patients with ulcerative colitis or Crohn's disease? A randomized controlled trial. Inflamm Bowel Dis. 2011;17:1863-1873. [PMID: 21287660 DOI: 10.1002/ibd.21575] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 6.0] [Reference Citation Analysis]
271 Hirono H, Watanabe K, Hasegawa K, Honma T, Ajioka Y, Ohkoshi S. A Case of Right-Sided Ulcerative Colitis with Mesalamine-Induced Hypersensitivity Reactions. Am J Case Rep 2018;19:623-9. [PMID: 29849018 DOI: 10.12659/AJCR.909644] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
272 Asgharpour A, Cheng J, Bickston SJ. Adalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trial. Clin Exp Gastroenterol 2013;6:153-60. [PMID: 24039442 DOI: 10.2147/CEG.S35163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 0.1] [Reference Citation Analysis]
273 Yarlas A, Maher S, Bayliss M, Lovley A, Cappelleri JC, Bushmakin AG, DiBonaventura MD. The Inflammatory Bowel Disease Questionnaire in Randomized Controlled Trials of Treatment for Ulcerative Colitis: Systematic Review and Meta-Analysis. J Patient Cent Res Rev 2020;7:189-205. [PMID: 32377552 DOI: 10.17294/2330-0698.1722] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
274 Mege D, Monsinjon M, Zappa M, Stefanescu C, Treton X, Maggiori L, Bouhnik Y, Panis Y. Is abdominal CT useful for the management of patients with severe acute colitis complicating inflammatory bowel disease? A study in 54 consecutive patients. Colorectal Dis 2017;19:O97-O102. [DOI: 10.1111/codi.13640] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
275 Achleitner U, Coenen M, Colombel J, Peyrin-biroulet L, Sahakyan N, Cieza A. Identification of areas of functioning and disability addressed in inflammatory bowel disease-specific patient reported outcome measures. Journal of Crohn's and Colitis 2012;6:507-17. [DOI: 10.1016/j.crohns.2011.11.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
276 Dong XY, Wu MX, Zhang HM, Lyu H, Qian JM, Yang H. Association between matrix Gla protein and ulcerative colitis according to DNA microarray data. Gastroenterol Rep (Oxf). 2020;8:66-75. [PMID: 32257220 DOI: 10.1093/gastro/goz038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
277 Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:96-109.e1. [PMID: 23770005 DOI: 10.1053/j.gastro.2013.06.010] [Cited by in Crossref: 382] [Cited by in F6Publishing: 365] [Article Influence: 47.8] [Reference Citation Analysis]
278 Bastida G, Nos P, Aguas M, Beltrán B, Iborra M, Ortiz V, Garrigues V, Estevan R, Ponce J. The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients. BMC Gastroenterol. 2010;10:26. [PMID: 20196836 DOI: 10.1186/1471-230x-10-26] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
279 Prieux-Klotz C, Nahon S, Amiot A, Sinayoko L, Galéano-Cassaz C, Chaussade S, Coriat R, Lahmek P, Abitbol V. Rate and Predictors of Mucosal Healing in Ulcerative Colitis Treated with Thiopurines: Results of a Multicentric Cohort Study. Dig Dis Sci 2017;62:473-80. [PMID: 27853898 DOI: 10.1007/s10620-016-4374-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
280 Bennebroek Evertsz' F, Thijssens NA, Stokkers PC, Grootenhuis MA, Bockting CL, Nieuwkerk PT, Sprangers MA. Do Inflammatory Bowel Disease patients with anxiety and depressive symptoms receive the care they need? J Crohns Colitis 2012;6:68-76. [PMID: 22261530 DOI: 10.1016/j.crohns.2011.07.006] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 7.1] [Reference Citation Analysis]
281 Acovic A, Simovic Markovic B, Gazdic M, Arsenijevic A, Jovicic N, Gajovic N, Jovanovic M, Zdravkovic N, Kanjevac T, Harrell CR, Fellabaum C, Dolicanin Z, Djonov V, Arsenijevic N, Lukic ML, Volarevic V. Indoleamine 2,3-dioxygenase-dependent expansion of T-regulatory cells maintains mucosal healing in ulcerative colitis. Therap Adv Gastroenterol. 2018;11:1756284818793558. [PMID: 30159037 DOI: 10.1177/1756284818793558] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
282 Sandborn WJ, Bhandari BR, Fogel R, Onken J, Yen E, Zhao X, Jiang Z, Ge D, Xin Y, Ye Z, French D, Silverman JA, Kanwar B, Subramanian GM, McHutchison JG, Lee SD, Shackelton LM, Pai RK, Levesque BG, Feagan BG. Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis. Aliment Pharmacol Ther 2016;44:157-69. [PMID: 27218676 DOI: 10.1111/apt.13653] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 7.4] [Reference Citation Analysis]
283 Naganuma M, Hosoe N, Kanai T, Ogata H. Recent trends in diagnostic techniques for inflammatory bowel disease. Korean J Intern Med 2015;30:271-8. [PMID: 25995657 DOI: 10.3904/kjim.2015.30.3.271] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
284 Rizzo G, Armuzzi A, Pugliese D, Verbo A, Papa A, Mattana C, Rapaccini GL, Guidi L, Coco C. Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. Int J Colorectal Dis. 2011;26:1435-1444. [PMID: 21594668 DOI: 10.1007/s00384-011-1236-2] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 4.8] [Reference Citation Analysis]
285 Baumgart DC, Metzke D, Guckelberger O, Pascher A, Grötzinger C, Przesdzing I, Dörffel Y, Schmitz J, Thomas S. Aberrant plasmacytoid dendritic cell distribution and function in patients with Crohn's disease and ulcerative colitis. Clin Exp Immunol 2011;166:46-54. [PMID: 21762123 DOI: 10.1111/j.1365-2249.2011.04439.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 4.4] [Reference Citation Analysis]
286 Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W, Colombel JF, Vermeire S, Travis S, Lindsay JO, van Assche G. [Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis (Spanish version)]. Rev Gastroenterol Mex 2014;79:263-89. [PMID: 25487134 DOI: 10.1016/j.rgmx.2014.10.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
287 Lopes S, Andrade P, Afonso J, Cunha R, Rodrigues-Pinto E, Ramos I, Macedo G, Magro F. Monitoring Crohn's disease activity: endoscopy, fecal markers and computed tomography enterography. Therap Adv Gastroenterol 2018;11:1756284818769075. [PMID: 29760785 DOI: 10.1177/1756284818769075] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
288 Bressenot A, Salleron J, Bastien C, Danese S, Boulagnon-Rombi C, Peyrin-Biroulet L. Comparing histological activity indexes in UC. Gut. 2015;64:1412-1418. [PMID: 25246423 DOI: 10.1136/gutjnl-2014-307477] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 10.0] [Reference Citation Analysis]
289 Hoivik ML, Bernklev T, Moum B. Need for standardization in population-based quality of life studies: a review of the current literature. Inflamm Bowel Dis. 2010;16:525-536. [PMID: 19637337 DOI: 10.1002/ibd.21032] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
290 Rosenberg L, Nanda KS, Zenlea T, Gifford A, Lawlor GO, Falchuk KR, Wolf JL, Cheifetz AS, Goldsmith JD, Moss AC. Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. Clin Gastroenterol Hepatol. 2013;11:991-996. [PMID: 23591275 DOI: 10.1016/j.cgh.2013.02.030] [Cited by in Crossref: 83] [Cited by in F6Publishing: 75] [Article Influence: 10.4] [Reference Citation Analysis]
291 Zenlea T, Yee EU, Rosenberg L, Boyle M, Nanda KS, Wolf JL, Falchuk KR, Cheifetz AS, Goldsmith JD, Moss AC. Histology Grade Is Independently Associated With Relapse Risk in Patients With Ulcerative Colitis in Clinical Remission: A Prospective Study. American Journal of Gastroenterology 2016;111:685-90. [DOI: 10.1038/ajg.2016.50] [Cited by in Crossref: 97] [Cited by in F6Publishing: 89] [Article Influence: 19.4] [Reference Citation Analysis]
292 Christensen B, Rubin DT. Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice. Curr Gastroenterol Rep 2016;18. [DOI: 10.1007/s11894-015-0477-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
293 Ewid M, Al Mutiri N, Al Omar K, Shamsan AN, Rathore AA, Saquib N, Salaas A, Al Sarraj O, Nasri Y, Attal A, Tawfiq A, Sherif H. Updated bone mineral density status in Saudi patients with inflammatory bowel disease. World J Gastroenterol 2020; 26(35): 5343-5353 [PMID: 32994692 DOI: 10.3748/wjg.v26.i35.5343] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
294 Limdi JK, Picco M, Farraye FA. A review of endoscopic scoring systems and their importance in a treat-to-target approach in inflammatory bowel disease (with videos). Gastrointestinal Endoscopy 2020;91:733-45. [DOI: 10.1016/j.gie.2019.11.032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
295 Zhang Z, Kennedy H. Ulcerative colitis: current medical therapy and strategies for improving medication adherence. Eur J Gastroenterol Hepatol. 2009;21:1-8. [PMID: 19011573 DOI: 10.1097/MEG.0b013e32830bfb88] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
296 Yarlas A, Willian MK, Nag A. The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine. Qual Life Res 2021;30:1925-38. [PMID: 33651279 DOI: 10.1007/s11136-021-02787-4] [Reference Citation Analysis]
297 Walsh A, Travis S. What's app? Electronic health technology in inflammatory bowel disease. Intest Res 2018;16:366-73. [PMID: 30090035 DOI: 10.5217/ir.2018.16.3.366] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
298 Huynh HQ, deBruyn J, Guan L, Diaz H, Li M, Girgis S, Turner J, Fedorak R, Madsen K. Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2009;15:760-768. [PMID: 19067432 DOI: 10.1002/ibd.20816] [Cited by in Crossref: 83] [Cited by in F6Publishing: 72] [Article Influence: 6.9] [Reference Citation Analysis]
299 Zhang T, Cui B, Li P, He Z, Long C, Wei L, Peng Z, Ji G, Zhang F. Short-Term Surveillance of Cytokines and C-Reactive Protein Cannot Predict Efficacy of Fecal Microbiota Transplantation for Ulcerative Colitis. PLoS One 2016;11:e0158227. [PMID: 27347881 DOI: 10.1371/journal.pone.0158227] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
300 Cordes F, Lenker E, Weinhage T, Spille LJ, Bettenworth D, Varga G, Schmidt HH, Foell D. Impaired IFN-γ-dependent STAT3 Activation Is Associated With Dysregulation of Regulatory and Inflammatory Signaling in Monocytes of Ulcerative Colitis Patients. Inflamm Bowel Dis 2021;27:887-901. [PMID: 33165509 DOI: 10.1093/ibd/izaa280] [Reference Citation Analysis]
301 Ylisaukko-Oja T, Aaltonen J, Nuutinen H, Blomster T, Jussila A, Pajala M, Salminen K, Moilanen V, Hakala K, Kellokumpu M, Toljamo K, Rautiainen H, Kuisma J, Peräaho M, Molander P, Silvennoinen J, Liukkonen V, Henricson H, Tillonen J, Esterinen M, Nielsen C, Hirsi E, Lääne M, Suhonen UM, Vihriälä I, Mäkelä P, Puhto M, Punkkinen J, Sulonen H, Herrala S, Jokelainen J, Tamminen K, Sipponen T. High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO). Scand J Gastroenterol 2018;53:158-67. [PMID: 29258369 DOI: 10.1080/00365521.2017.1416160] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
302 Yoshino T, Yamakawa K, Nishimura S, Watanabe K, Yazumi S. The predictive variable regarding relapse in patients with ulcerative colitis after achieving endoscopic mucosal healing. Intest Res 2016;14:37-42. [PMID: 26884733 DOI: 10.5217/ir.2016.14.1.37] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
303 Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, Panaccione R, Steinhart AH, Tse F, Feagan B; Toronto Ulcerative Colitis Consensus Group. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015;148:1035-1058.e3. [PMID: 25747596 DOI: 10.1053/j.gastro.2015.03.001] [Cited by in Crossref: 211] [Cited by in F6Publishing: 179] [Article Influence: 35.2] [Reference Citation Analysis]
304 Kristensen V, Lauritzen T, Jelsness-JØrgensen LP, Moum B. Validation of a new extraction device for measuring faecal calprotectin in inflammatory bowel disease, and comparison to established extraction methods. Scand J Clin Lab Invest 2015;75:355-61. [PMID: 25856663 DOI: 10.3109/00365513.2015.1030765] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
305 Ibargoyen-Roteta N, Gutiérrez-Ibarluzea I, Rico-Iturrioz R, López-Argumedo M, Reviriego-Rodrigo E, Cabriada-Nuño JL, Schünemann HJ. The GRADE approach for assessing new technologies as applied to apheresis devices in ulcerative colitis. Implement Sci 2010;5:48. [PMID: 20553616 DOI: 10.1186/1748-5908-5-48] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
306 Kristensen VA, Valeur J, Brackmann S, Jahnsen J, Brunborg C, Tveito K. Attention deficit and hyperactivity disorder symptoms respond to gluten-free diet in patients with coeliac disease. Scandinavian Journal of Gastroenterology 2019;54:571-6. [DOI: 10.1080/00365521.2019.1608467] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
307 Alrubaiy L, Hutchings HA, Williams JG. Protocol for a prospective multicentre cohort study to develop and validate two new outcome measures for patients with inflammatory bowel disease. BMJ Open 2013;3:e003192. [PMID: 23842503 DOI: 10.1136/bmjopen-2013-003192] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
308 Bezzio C, Manes G, Schettino M, Arena I, de Nucci G, Della Corte C, Devani M, Mandelli E, Morganti D, Omazzi B, Pellegrini L, Picascia D, Redaelli D, Reati R, Saibeni S. Inflammatory bowel disease in a colorectal cancer screening population: Diagnosis and follow-up. Dig Liver Dis. 2021;53:587-591. [PMID: 32863160 DOI: 10.1016/j.dld.2020.07.036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
309 Maggiori L, Panis Y. Surgical management of IBD--from an open to a laparoscopic approach. Nat Rev Gastroenterol Hepatol. 2013;10:297-306. [PMID: 23419288 DOI: 10.1038/nrgastro.2013.30] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
310 Suárez J, Romero-Zerbo Y, Márquez L, Rivera P, Iglesias M, Bermúdez-Silva FJ, Andreu M, Rodríguez de Fonseca F. Ulcerative colitis impairs the acylethanolamide-based anti-inflammatory system reversal by 5-aminosalicylic acid and glucocorticoids. PLoS One 2012;7:e37729. [PMID: 22662201 DOI: 10.1371/journal.pone.0037729] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
311 Aguas M, Del Hoyo J, Faubel R, Muñoz D, Domínguez D, Bastida G, Navarro B, Barrios A, Valdivieso B, Correcher M, Nos P. A Web-Based Telemanagement System for Patients With Complex Inflammatory Bowel Disease: Protocol for a Randomized Controlled Clinical Trial. JMIR Res Protoc 2018;7:e190. [PMID: 30578197 DOI: 10.2196/resprot.9639] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
312 Marchal Bressenot A. Which evidence for a treat to target strategy in ulcerative colitis? Best Practice & Research Clinical Gastroenterology 2018;32-33:3-8. [DOI: 10.1016/j.bpg.2018.05.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
313 Liu X, Beaumont M, Walker F, Chaumontet C, Andriamihaja M, Matsumoto H, Khodorova N, Lan A, Gaudichon C, Benamouzig R, Tomé D, Davila AM, Marie JC, Blachier F. Beneficial effects of an amino acid mixture on colonic mucosal healing in rats. Inflamm Bowel Dis 2013;19:2895-905. [PMID: 24193156 DOI: 10.1097/01.MIB.0000435849.17263.c5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 2.9] [Reference Citation Analysis]
314 Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;20:CD004115. [PMID: 20091560 DOI: 10.1002/14651858.cd004115.pub2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
315 Dignass A, Schnabel R, Romatowski J, Pavlenko V, Dorofeyev A, Derova J, Jonaitis L, Dilger K, Nacak T, Greinwald R; International SAT-25 Study Group. Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial. United European Gastroenterol J 2018;6:138-47. [PMID: 29435324 DOI: 10.1177/2050640617703842] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
316 Koido S, Ohkusa T, Takakura K, Odahara S, Tsukinaga S, Yukawa T, Mitobe J, Kajihara M, Uchiyama K, Arakawa H, Tajiri H. Clinical significance of serum procalcitonin in patients with ulcerative colitis. World J Gastroenterol 2013; 19(45): 8335-8341 [PMID: 24363525 DOI: 10.3748/wjg.v19.i45.8335] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
317 Ye L, Zhang YP, Yu N, Jia YX, Wan SJ, Wang FY. Serum platelet factor 4 is a reliable activity parameter in adult patients with inflammatory bowel disease: A pilot study. Medicine (Baltimore) 2017;96:e6323. [PMID: 28296751 DOI: 10.1097/MD.0000000000006323] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
318 Mayer L, Sandborn WJ, Stepanov Y, Geboes K, Hardi R, Yellin M, Tao X, Xu LA, Salter-Cid L, Gujrathi S. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 2014;63:442-450. [PMID: 23461895 DOI: 10.1136/gutjnl-2012-303424] [Cited by in Crossref: 95] [Cited by in F6Publishing: 82] [Article Influence: 11.9] [Reference Citation Analysis]
319 Farrell D, Savage E. Symptom burden in inflammatory bowel disease: rethinking conceptual and theoretical underpinnings. Int J Nurs Pract 2010;16:437-42. [PMID: 20854340 DOI: 10.1111/j.1440-172X.2010.01867.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
320 Oliva S, Thomson M, de Ridder L, Martín-de-Carpi J, Van Biervliet S, Braegger C, Dias JA, Kolacek S, Miele E, Buderus S, Bronsky J, Winter H, Navas-López VM, Assa A, Chong SKF, Afzal NA, Smets F, Shaoul R, Hussey S, Turner D, Cucchiara S. Endoscopy in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto IBD Group of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:414-30. [PMID: 30130311 DOI: 10.1097/MPG.0000000000002092] [Cited by in Crossref: 31] [Cited by in F6Publishing: 10] [Article Influence: 15.5] [Reference Citation Analysis]
321 Kang YS, Moon HH, Lee SE, Lim YJ, Kang HW. Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series. Dig Dis Sci. 2015;60:951-956. [PMID: 25326115 DOI: 10.1007/s10620-014-3392-z] [Cited by in Crossref: 89] [Cited by in F6Publishing: 77] [Article Influence: 12.7] [Reference Citation Analysis]
322 Ahmad H, Berzin TM, Yu HJ, Huang CS, Mishkin DS. Central endoscopy reads in inflammatory bowel disease clinical trials: The role of the imaging core lab. Gastroenterol Rep (Oxf) 2014;2:201-6. [PMID: 24994835 DOI: 10.1093/gastro/gou033] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
323 Giugliano FP, Strisciuglio C, Martinelli M, Andreozzi M, Cenni S, Campione S, D’armiento M, Staiano A, Miele E. Does Azathioprine induce endoscopic and histologic healing in pediatric inflammatory bowel disease? A prospective, observational study. Digestive and Liver Disease 2018;50:240-6. [DOI: 10.1016/j.dld.2017.10.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
324 Frigstad SO, Høivik ML, Jahnsen J, Cvancarova M, Grimstad T, Berset IP, Huppertz-Hauss G, Hovde Ø, Bernklev T, Moum B, Jelsness-Jørgensen LP. Pain Severity and Vitamin D Deficiency in IBD Patients. Nutrients 2019;12:E26. [PMID: 31877637 DOI: 10.3390/nu12010026] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
325 Bertani L, Rossari F, Barberio B, Demarzo MG, Tapete G, Albano E, Baiano Svizzero G, Ceccarelli L, Mumolo MG, Brombin C, de Bortoli N, Bellini M, Marchi S, Bodini G, Savarino E, Costa F. Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio. Inflamm Bowel Dis. 2020;26:1579-1587. [PMID: 32232392 DOI: 10.1093/ibd/izaa062] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
326 Molander P, Färkkilä M, Kemppainen H, Blomster T, Jussila A, Mustonen H, Sipponen T. Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα-blocking agents. Scandinavian Journal of Gastroenterology 2017;52:284-90. [DOI: 10.1080/00365521.2016.1250942] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
327 Palone F, Vitali R, Cucchiara S, Mennini M, Armuzzi A, Pugliese D, DʼIncà R, Barberio B, Stronati L. Fecal HMGB1 Reveals Microscopic Inflammation in Adult and Pediatric Patients with Inflammatory Bowel Disease in Clinical and Endoscopic Remission. Inflamm Bowel Dis 2016;22:2886-93. [PMID: 27755215 DOI: 10.1097/MIB.0000000000000938] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 7.3] [Reference Citation Analysis]
328 Dias AM, Dourado J, Lago P, Cabral J, Marcos-Pinto R, Salgueiro P, Almeida CR, Carvalho S, Fonseca S, Lima M, Vilanova M, Dinis-Ribeiro M, Reis CA, Pinho SS. Dysregulation of T cell receptor N-glycosylation: a molecular mechanism involved in ulcerative colitis. Hum Mol Genet 2014;23:2416-27. [PMID: 24334766 DOI: 10.1093/hmg/ddt632] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
329 Goutorbe F, Goutte M, Minet-Quinard R, Boucher AL, Pereira B, Bommelaer G, Buisson A. Endoscopic Factors Influencing Fecal Calprotectin Value in Crohn's Disease. J Crohns Colitis. 2015;9:1113-1119. [PMID: 26351383 DOI: 10.1093/ecco-jcc/jjv150] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]
330 Arai T, Takeuchi K, Miyamura M, Ishikawa R, Yamada A, Katsumata M, Igarashi Y, Suzuki Y. Level of Fecal Calprotectin Correlates With Severity of Small Bowel Crohn’s Disease, Measured by Balloon-assisted Enteroscopy and Computed Tomography Enterography. Clinical Gastroenterology and Hepatology 2017;15:56-62. [DOI: 10.1016/j.cgh.2016.08.015] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
331 Mocciaro F, Pecoraro GM, Di Mitri R, Scimeca D, Bossa F, Russo G, Martino G, Costanza V, Profita MA, Orlando C, Profeta G, Tinè F. Nurse in patients’ health status assessment: Data from a pilot study assessing agreement among nurse and gastroenterologist in computing IBD-clinical scores. Digestive and Liver Disease 2017;49:1110-4. [DOI: 10.1016/j.dld.2017.06.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
332 Casella G, Corbetta D, Zolezzi M, Di Bella C, Villanacci V, Salemme M, Milanesi U, Antonelli E, Baldini V, Bassotti G. Symptomatic sensorineural hearing loss in patients with ulcerative colitis. Tech Coloproctol 2015;19:729-31. [DOI: 10.1007/s10151-015-1349-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
333 Frontali A, Cohen L, Bridoux V, Myrelid P, Sica G, Poggioli G, Espin E, Beyer-Berjot L, Laharie D, Spinelli A, Zerbib P, Sampietro G, Frasson M, Louis E, Danese S, Fumery M, Denost Q, Altwegg R, Nancey S, Michelassi F, Treton X, Panis Y. Segmental colectomy for ulcerative colitis: is there a place in selected patients without active colitis ? An international multicentric retrospective study in 72 patients. J Crohns Colitis 2020:jjaa107. [PMID: 32498084 DOI: 10.1093/ecco-jcc/jjaa107] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
334 Lowe SC, Sauk JS, Limketkai BN, Kwaan MR. Declining Rates of Surgery for Inflammatory Bowel Disease in the Era of Biologic Therapy. J Gastrointest Surg 2021;25:211-9. [PMID: 33140318 DOI: 10.1007/s11605-020-04832-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
335 Rutka M, Milassin Á, Szepes Z, SzŰcs M, Nyári T, Bálint A, Bor R, Molnár T, Farkas K. Is mucosal healing more common than clinical remission in ulcerative colitis? - Is it the truth or only a myth coming from the studies? Scand J Gastroenterol 2015;50:985-90. [PMID: 25733077 DOI: 10.3109/00365521.2015.1018313] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
336 Freeman HJ. Medical management of ulcerative colitis with a specific focus on 5-aminosalicylates. Clin Med Insights Gastroenterol 2012;5:77-83. [PMID: 24833937 DOI: 10.4137/CGast.S8673] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
337 Chen YH, Wang L, Feng SY, Cai WM, Chen XF, Huang ZM. The Relationship between C-Reactive Protein/Albumin Ratio and Disease Activity in Patients with Inflammatory Bowel Disease. Gastroenterol Res Pract 2020;2020:3467419. [PMID: 32655630 DOI: 10.1155/2020/3467419] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
338 Ramadass SK, Jabaris SL, Perumal RK, Hairulislam VI, Gopinath A, Madhan B. Type I collagen and its daughter peptides for targeting mucosal healing in ulcerative colitis: A new treatment strategy. European Journal of Pharmaceutical Sciences 2016;91:216-24. [DOI: 10.1016/j.ejps.2016.05.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
339 Neri B, Mossa M, Scucchi L, Sena G, Palmieri G, Biancone L. Histological scores in inflammatory bowel disease. J Dig Dis 2021;22:9-22. [PMID: 32897005 DOI: 10.1111/1751-2980.12937] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
340 Devlin SM, Melmed GY, Irving PM, Rubin DT, Kornbluth A, Kozuch PL, Raffals LE, Velayos FS, Sparrow MP, Baidoo L, Bressler B, Cheifetz AS, Jones J, Kaplan GG, Siegel CA. Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease: Results from a RAND Appropriateness Panel. Inflammatory Bowel Diseases 2016;22:1418-24. [DOI: 10.1097/mib.0000000000000764] [Cited by in Crossref: 17] [Cited by in F6Publishing: 3] [Article Influence: 3.4] [Reference Citation Analysis]
341 Theocharidou E, Balaska A, Vogiatzis K, Tellis CC, Gossios TD, Athyros VG, Tselepis AD, Karagiannis A. Hypertrophic Mesenteric Adipose Tissue May Play a Role in Atherogenesis in Inflammatory Bowel Diseases: . Inflammatory Bowel Diseases 2016;22:2206-12. [DOI: 10.1097/mib.0000000000000873] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
342 Murthy SK, Steinhart AH, Tinmouth J, Austin PC, Daneman N, Nguyen GC. Impact of Clostridium difficile colitis on 5-year health outcomes in patients with ulcerative colitis. Aliment Pharmacol Ther. 2012;36:1032-1039. [PMID: 23061526 DOI: 10.1111/apt.12073] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 5.2] [Reference Citation Analysis]
343 Li Y, Wang Y, Liu Y, Wang Y, Zuo X, Li Y, Lu X. The possible role of the novel cytokines il-35 and il-37 in inflammatory bowel disease. Mediators Inflamm 2014;2014:136329. [PMID: 25214710 DOI: 10.1155/2014/136329] [Cited by in Crossref: 44] [Cited by in F6Publishing: 52] [Article Influence: 6.3] [Reference Citation Analysis]
344 López-Palacios N, Mendoza JL, Taxonera C, Lana R, López-Jamar JM, Díaz-Rubio M. Mucosal healing for predicting clinical outcome in patients with ulcerative colitis using thiopurines in monotherapy. Eur J Intern Med 2011;22:621-5. [PMID: 22075292 DOI: 10.1016/j.ejim.2011.06.017] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
345 Baudet A, Rahmi G, Bretagne AL, Gloro R, Justum AM, Reimund JM. Severe ulcerative colitis: present medical treatment strategies. Expert Opin Pharmacother. 2008;9:447-457. [PMID: 18220494 DOI: 10.1517/14656566.9.3.447] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
346 Maeda Y, Ohtsuka K, Kudo SE, Wakamura K, Mori Y, Ogata N, Wada Y, Misawa M, Yamauchi A, Hayashi S, Kudo T, Hayashi T, Miyachi H, Yamamura F, Ishida F, Inoue H, Hamatani S. Endocytoscopic narrow-band imaging efficiency for evaluation of inflammatory activity in ulcerative colitis. World J Gastroenterol 2015; 21(7): 2108-2115 [PMID: 25717245 DOI: 10.3748/wjg.v21.i7.2108] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
347 Kristensen V, Klepp P, Cvancarova M, Røseth A, Skar V, Moum B. Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin. J Crohns Colitis. 2015;9:164-169. [PMID: 25518057 DOI: 10.1093/ecco-jcc/jju015] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 7.6] [Reference Citation Analysis]
348 Seah D, De Cruz P. Review article: the practical management of acute severe ulcerative colitis. Aliment Pharmacol Ther. 2016;43:482-513. [PMID: 26725569 DOI: 10.1111/apt.13491] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 10.0] [Reference Citation Analysis]
349 Langer V, Vivi E, Regensburger D, Winkler TH, Waldner MJ, Rath T, Schmid B, Skottke L, Lee S, Jeon NL, Wohlfahrt T, Kramer V, Tripal P, Schumann M, Kersting S, Handtrack C, Geppert CI, Suchowski K, Adams RH, Becker C, Ramming A, Naschberger E, Britzen-Laurent N, Stürzl M. IFN-γ drives inflammatory bowel disease pathogenesis through VE-cadherin-directed vascular barrier disruption. J Clin Invest 2019;129:4691-707. [PMID: 31566580 DOI: 10.1172/JCI124884] [Cited by in Crossref: 36] [Cited by in F6Publishing: 23] [Article Influence: 36.0] [Reference Citation Analysis]
350 Bai M, Xing L, Feng J, Huang L, Li J, Liang G. Mean platelet volume as a possible marker for monitoring the disease activity in ulcerative colitis. Int Jnl Lab Hem 2016;38:e77-9. [DOI: 10.1111/ijlh.12495] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
351 Fernandes SR, Pinto JSLD, Marques da Costa P, Correia L; GEDII. Disagreement Among Gastroenterologists Using the Mayo and Rutgeerts Endoscopic Scores. Inflammatory Bowel Diseases 2018;24:254-60. [DOI: 10.1093/ibd/izx066] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
352 Molander P, af Björkesten CG, Mustonen H, Haapamäki J, Vauhkonen M, Kolho KL, Färkkilä M, Sipponen T. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents. Inflamm Bowel Dis. 2012;18:2011-2017. [PMID: 22223566 DOI: 10.1002/ibd.22863] [Cited by in Crossref: 119] [Cited by in F6Publishing: 114] [Article Influence: 13.2] [Reference Citation Analysis]
353 Jovanovic M, Gajovic N, Zdravkovic N, Jovanovic M, Jurisevic M, Vojvodic D, Maric V, Arsenijevic A, Jovanovic I. Fecal Galectin-3: A New Promising Biomarker for Severity and Progression of Colorectal Carcinoma. Mediators Inflamm. 2018;2018:8031328. [PMID: 29849497 DOI: 10.1155/2018/8031328] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
354 Song CS, Park DI, Yoon MY, Seok HS, Park JH, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI. Association between red cell distribution width and disease activity in patients with inflammatory bowel disease. Dig Dis Sci. 2012;57:1033-1038. [PMID: 22147246 DOI: 10.1007/s10620-011-1978-2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 6.1] [Reference Citation Analysis]
355 Sandborn WJ, Travis S, Moro L, Jones R, Gautille T, Bagin R, Huang M, Yeung P, Ballard ED. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology. 2012;143:1218-1226.e1-2. [PMID: 22892337 DOI: 10.1053/j.gastro.2012.08.003] [Cited by in Crossref: 148] [Cited by in F6Publishing: 131] [Article Influence: 16.4] [Reference Citation Analysis]
356 van Langenberg DR, Gibson PR. Systematic review: fatigue in inflammatory bowel disease. Aliment Pharmacol Ther. 2010;32:131-143. [PMID: 20456309 DOI: 10.1111/j.1365-2036.2010.04347.x] [Cited by in Crossref: 112] [Cited by in F6Publishing: 104] [Article Influence: 10.2] [Reference Citation Analysis]
357 Florholmen J. Mucosal healing in the era of biologic agents in treatment of inflammatory bowel disease. Scand J Gastroenterol. 2015;50:43-52. [PMID: 25523555 DOI: 10.3109/00365521.2014.977943] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
358 Paköz ZB, Çekiç C, Arabul M, Sarıtaş Yüksel E, İpek S, Vatansever S, Ünsal B. An Evaluation of the Correlation between Hepcidin Serum Levels and Disease Activity in Inflammatory Bowel Disease. Gastroenterol Res Pract 2015;2015:810942. [PMID: 25628652 DOI: 10.1155/2015/810942] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
359 Travis SP, Danese S, Kupcinskas L, Alexeeva O, D'Haens G, Gibson PR, Moro L, Jones R, Ballard ED, Masure J, Rossini M, Sandborn WJ. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomized CORE II study. Gut. 2014;63:433-441. [PMID: 23436336 DOI: 10.1136/gutjnl-2012-304258] [Cited by in Crossref: 154] [Cited by in F6Publishing: 131] [Article Influence: 19.3] [Reference Citation Analysis]
360 Bergqvist V, Kadivar M, Molin D, Angelison L, Hammarlund P, Olin M, Torp J, Grip O, Nilson S, Hertervig E, Lillienau J, Marsal J. Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease. Therap Adv Gastroenterol 2018;11:1756284818801244. [PMID: 30344642 DOI: 10.1177/1756284818801244] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
361 Rocha HVA, Gomes AS, Dornelas CB, Almada do Carmo F, Rodrigues CR, Castro H, dos Santos TC, Cabral LM. The Preparation and Evaluation of Sodium and Alkylammonium Montmorillonite and Polysaccharide Nanocomposites as Sustained Release Excipients. Polymer-Plastics Technology and Engineering 2008;47:1256-64. [DOI: 10.1080/03602550802497727] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
362 Bertani L, Baglietto L, Antonioli L, Fornai M, Tapete G, Albano E, Ceccarelli L, Mumolo MG, Pellegrini C, Lucenteforte E, de Bortoli N, Bellini M, Marchi S, Blandizzi C, Costa F. Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients. Br J Clin Pharmacol 2020;86:1296-305. [PMID: 32027388 DOI: 10.1111/bcp.14235] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
363 Huoponen S, Eberl A, Räsänen P, Roine RP, Sipponen T, Arkkila P, Blom M. Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease. Medicine (Baltimore) 2020;99:e18723. [PMID: 31914087 DOI: 10.1097/MD.0000000000018723] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
364 Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, Schnell P, Bernhardt CA, Mary JY, Sandborn WJ. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013;145:987-995. [PMID: 23891974 DOI: 10.1053/j.gastro.2013.07.024] [Cited by in Crossref: 222] [Cited by in F6Publishing: 182] [Article Influence: 27.8] [Reference Citation Analysis]
365 Quezada SM, Briscoe J, Cross RK. Complementary and Alternative Medicine. Inflamm Bowel Dis 2016;22:1523-30. [PMID: 27057686 DOI: 10.1097/MIB.0000000000000761] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
366 Lobatón T, Azuara D, Rodríguez-Moranta F, Loayza C, Sanjuan X, de Oca J, Fernández-Robles A, Guardiola J, Capellá G. Relationship between methylation and colonic inflammation in inflammatory bowel disease. World J Gastroenterol 2014; 20(30): 10591-10598 [PMID: 25132780 DOI: 10.3748/wjg.v20.i30.10591] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
367 Ha C, Kornbluth A. Mucosal healing in inflammatory bowel disease: where do we stand? Curr Gastroenterol Rep. 2010;12:471-478. [PMID: 20886319 DOI: 10.1007/s11894-010-0146-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
368 Wang D, Shi K, Wang Y, Zou D, Guo S, Li T, Xu H, Ma X, Liu J, Song H, Yang W, Li Y. Effect of Huangqin Tang on Colonic Gene Expression in Rats with Ulcerative Colitis. Int J Genomics 2020;2020:4238757. [PMID: 32300604 DOI: 10.1155/2020/4238757] [Reference Citation Analysis]
369 Romanini L, Passamonti M, Navarria M, Lanzarotto F, Villanacci V, Grazioli L, Calliada F, Maroldi R. Quantitative analysis of contrast-enhanced ultrasonography of the bowel wall can predict disease activity in inflammatory bowel disease. Eur J Radiol. 2014;83:1317-1323. [PMID: 24908589 DOI: 10.1016/j.ejrad.2014.05.012] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 5.7] [Reference Citation Analysis]
370 Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114:384-413. [PMID: 30840605 DOI: 10.14309/ajg.0000000000000152] [Cited by in Crossref: 300] [Cited by in F6Publishing: 253] [Article Influence: 150.0] [Reference Citation Analysis]
371 Pai RK, Jairath V, Vande Casteele N, Rieder F, Parker CE, Lauwers GY. The emerging role of histologic disease activity assessment in ulcerative colitis. Gastrointestinal Endoscopy 2018;88:887-98. [DOI: 10.1016/j.gie.2018.08.018] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 11.7] [Reference Citation Analysis]
372 Abdelazeem MA, El-sayed M. The pattern of CD44 and matrix metalloproteinase 9 expression is a useful predictor of ulcerative colitis–associated dysplasia and neoplasia. Annals of Diagnostic Pathology 2015;19:369-74. [DOI: 10.1016/j.anndiagpath.2015.08.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
373 Simsek HD, Basyigit S, Aktas B, Simsek GG, Vargol E, Kucukazman M, Nazlıgul Y. Assessment of the Correlation between Endoscopic Activity and Histological Activity in Ulcerative Colitis Patients. Med Princ Pract 2016;25:378-84. [PMID: 26985865 DOI: 10.1159/000445502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
374 Neumann H, Neurath MF. UCCIS—a reproducible tool to assess mucosal healing. Nat Rev Gastroenterol Hepatol 2012;9:692-4. [DOI: 10.1038/nrgastro.2012.198] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
375 Lightner AL, Vogel JD, Carmichael JC, Keller DS, Shah SA, Mahadevan U, Kane SV, Paquette IM, Steele SR, Feingold DL. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Crohn's Disease. Dis Colon Rectum. 2020;63:1028-1052. [PMID: 32692069 DOI: 10.1097/dcr.0000000000001716] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 10.0] [Reference Citation Analysis]
376 Ikeya K, Sugimoto K, Kawasaki S, Iida T, Maruyama Y, Watanabe F, Hanai H. Tacrolimus for remission induction in ulcerative colitis: Mayo endoscopic subscore 0 and 1 predict long-term prognosis. Dig Liver Dis. 2015;47:365-371. [PMID: 25682993 DOI: 10.1016/j.dld.2015.01.149] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
377 Travis SPL, Higgins PDR, Orchard T, Van Der Woude CJ, Panaccione R, Bitton A, O’morain C, Panés J, Sturm A, Reinisch W, Kamm MA, D’haens G. Review article: defining remission in ulcerative colitis: Review: remission in ulcerative colitis. Alimentary Pharmacology & Therapeutics 2011;34:113-24. [DOI: 10.1111/j.1365-2036.2011.04701.x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 11.3] [Reference Citation Analysis]
378 Jairath V, Khanna R, Zou GY, Stitt L, Mosli M, Vandervoort MK, D'Haens G, Sandborn WJ, Feagan BG, Levesque BG. Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. Aliment Pharmacol Ther. 2015;42:1200-1210. [PMID: 26388424 DOI: 10.1111/apt.13408] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 10.2] [Reference Citation Analysis]
379 Sun H, Lee JJ, Papadopoulos EJ, Lee CS, Nelson RM, Sachs HC, Rodriguez WJ, Mulberg AE. Alternate endpoints and clinical outcome assessments in pediatric ulcerative colitis registration trials. J Pediatr Gastroenterol Nutr. 2014;58:12-17. [PMID: 24121142 DOI: 10.1097/mpg.0000000000000186] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
380 Sicilia B, García-López S, González-Lama Y, Zabana Y, Hinojosa J, Gomollón F; Grupo Español de Trabajo de Enfermedad de Crohn., Colitis Ulcerosa o Spanish Group for Working on Crohn's Disease and Ulcerative Colitis (GETECCU). GETECCU 2020 guidelines for the treatment of ulcerative colitis. Developed using the GRADE approach. Gastroenterol Hepatol 2020;43 Suppl 1:1-57. [PMID: 32807301 DOI: 10.1016/j.gastrohep.2020.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
381 Sun H, Vesely R, Nelson RM, Taminiau J, Szitanyi P, Isaac M, Klein A, Uzu S, Griebel D, Mulberg AE. Steps Toward Harmonization for Clinical Development of Medicines in Pediatric Ulcerative Colitis—A Global Scientific Discussion, Part 2: Data Extrapolation, Trial Design, and Pharmacokinetics. Journal of Pediatric Gastroenterology & Nutrition 2014;58:684-8. [DOI: 10.1097/mpg.0000000000000322] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
382 Zhai H, Liu A, Huang W, Liu X, Feng S, Wu J, Yao Y, Wang C, Li Q, Hao Q, Hu J, Zhang S. Increasing rate of inflammatory bowel disease: a 12-year retrospective study in NingXia, China. BMC Gastroenterol 2016;16:2. [PMID: 26754840 DOI: 10.1186/s12876-015-0405-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
383 Kuznetsov NV, Zargari A, Gielen AW, von Stein OD, Musch E, Befrits R, Lofberg R, von Stein P. Biomarkers can predict potential clinical responders to DIMS0150 a toll-like receptor 9 agonist in ulcerative colitis patients. BMC Gastroenterol 2014;14:79. [PMID: 24758565 DOI: 10.1186/1471-230X-14-79] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 2.1] [Reference Citation Analysis]
384 D'Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, Geens P, Iwens D, Aerden I, Van Assche G, Van Olmen G, Rutgeerts P. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218-2224. [PMID: 22344983 DOI: 10.1002/ibd.22917] [Cited by in Crossref: 474] [Cited by in F6Publishing: 436] [Article Influence: 52.7] [Reference Citation Analysis]
385 Kim JH, Cheon JH, Park Y, Lee HJ, Park SJ, Kim TI, Kim WH. Effect of mucosal healing (Mayo 0) on clinical relapse in patients with ulcerative colitis in clinical remission. Scand J Gastroenterol 2016;51:1069-74. [PMID: 26895215 DOI: 10.3109/00365521.2016.1150503] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
386 Zhao X, Li L, Li X, Li J, Wang D, Zhang H. The Relationship between Serum Bilirubin and Inflammatory Bowel Disease. Mediators Inflamm 2019;2019:5256460. [PMID: 31148945 DOI: 10.1155/2019/5256460] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
387 Turner D, Mack D, Leleiko N, Walters TD, Uusoue K, Leach ST, Day AS, Crandall W, Silverberg MS, Markowitz J. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology. 2010;138:2282-2291. [PMID: 20193683 DOI: 10.1053/j.gastro.2010.02.047] [Cited by in Crossref: 164] [Cited by in F6Publishing: 139] [Article Influence: 14.9] [Reference Citation Analysis]
388 Brandse JF, Bennink RJ, van Eeden S, Löwenberg M, van den Brink GR, DʼHaens GR. Performance of Common Disease Activity Markers as a Reflection of Inflammatory Burden in Ulcerative Colitis. Inflamm Bowel Dis 2016;22:1384-90. [PMID: 26978724 DOI: 10.1097/MIB.0000000000000746] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
389 Gledhill T, Bodger K. New and emerging treatments for ulcerative colitis: a focus on vedolizumab. Biologics. 2013;7:123-130. [PMID: 23723689 DOI: 10.2147/btt.s30416] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 0.1] [Reference Citation Analysis]
390 Lobatón T, Rodríguez-moranta F, Lopez A, Sánchez E, Rodríguez-alonso L, Guardiola J. A New Rapid Quantitative Test for Fecal Calprotectin Predicts Endoscopic Activity in Ulcerative Colitis: . Inflammatory Bowel Diseases 2013;19:1034-42. [DOI: 10.1097/mib.0b013e3182802b6e] [Cited by in Crossref: 81] [Cited by in F6Publishing: 29] [Article Influence: 10.1] [Reference Citation Analysis]
391 Bezzio C, Saibeni S, Variola A, Allocca M, Massari A, Gerardi V, Casini V, Ricci C, Zingone F, Amato A, Caprioli F, Lenti MV, Viganò C, Ascolani M, Bossa F, Castiglione F, Cortelezzi C, Grossi L, Milla M, Morganti D, Pastorelli L, Ribaldone DG, Sartini A, Soriano A, Manes G, Danese S, Fantini MC, Armuzzi A, Daperno M, Fiorino G; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut 2020;69:1213-7. [PMID: 32354990 DOI: 10.1136/gutjnl-2020-321411] [Cited by in Crossref: 154] [Cited by in F6Publishing: 136] [Article Influence: 154.0] [Reference Citation Analysis]
392 Poole CD, Connolly MP, Nielsen SK, Currie CJ, Marteau P. A comparison of physician-rated disease severity and patient reported outcomes in mild to moderately active ulcerative colitis. J Crohns Colitis. 2010;4:275-282. [PMID: 21122516 DOI: 10.1016/j.crohns.2009.11.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
393 Shinzaki S, Matsuoka K, Tanaka H, Takeshima F, Kato S, Torisu T, Ohta Y, Watanabe K, Nakamura S, Yoshimura N, Kobayashi T, Shiotani A, Hirai F, Hiraoka S, Watanabe M, Matsuura M, Nishimoto S, Mizuno S, Iijima H, Takehara T, Naka T, Kanai T, Matsumoto T. Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study. J Gastroenterol 2021;56:560-9. [PMID: 33942166 DOI: 10.1007/s00535-021-01793-0] [Reference Citation Analysis]
394 Hanauer SB. Review article: evolving concepts in treatment and disease modification in ulcerative colitis. Aliment Pharmacol Ther. 2008;27 Suppl 1:15-21. [PMID: 18307645 DOI: 10.1111/j.1365-2036.2008.03606.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
395 Brandse JF, van den Brink GR, Wildenberg ME, van der Kleij D, Rispens T, Jansen JM, Mathôt RA, Ponsioen CY, Löwenberg M, D’haens GR. Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis. Gastroenterology 2015;149:350-355.e2. [DOI: 10.1053/j.gastro.2015.04.016] [Cited by in Crossref: 237] [Cited by in F6Publishing: 196] [Article Influence: 39.5] [Reference Citation Analysis]
396 Manz M, Vavricka SR, Wanner R, Lakatos PL, Rogler G, Frei P, Safroneeva E, Schoepfer AM. Therapy of steroid-resistant inflammatory bowel disease. Digestion. 2012;86 Suppl 1:11-15. [PMID: 23051721 DOI: 10.1159/000341952] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
397 Amini Kadijani A, Asadzadeh Aghdaei H, Sorrentino D, Mirzaei A, Shahrokh S, Balaii H, Nguyen VQ, Mays JL, Reza Zali M. Transmembrane TNF-α Density, but not Soluble TNF-α Level, is Associated with Primary Response to Infliximab in Inflammatory Bowel Disease. Clin Transl Gastroenterol 2017;8:e117. [PMID: 28914262 DOI: 10.1038/ctg.2017.44] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
398 Zallot C, Peyrin-Biroulet L. Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr Gastroenterol Rep. 2013;15:315. [PMID: 23354742 DOI: 10.1007/s11894-013-0315-7] [Cited by in Crossref: 78] [Cited by in F6Publishing: 76] [Article Influence: 9.8] [Reference Citation Analysis]
399 Walsh AJ, Ghosh A, Brain AO, Buchel O, Burger D, Thomas S, White L, Collins GS, Keshav S, Travis SP. Comparing disease activity indices in ulcerative colitis. J Crohns Colitis. 2014;8:318-325. [PMID: 24120021 DOI: 10.1016/j.crohns.2013.09.010] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 7.8] [Reference Citation Analysis]
400 Lin X, Lofland J, Zhang L, Sloan S, Chamaa L, Marano C, Plevy S. Opioid Use in Patients With Inflammatory Bowel Disease. Crohn's & Colitis 360 2020;2:otaa009. [DOI: 10.1093/crocol/otaa009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
401 Ding ZH, Xu XP, Wang TR, Liang X, Ran ZH, Lu H. The prevalence of Helicobacter pylori infection in inflammatory bowel disease in China: A case-control study. PLoS One 2021;16:e0248427. [PMID: 33711050 DOI: 10.1371/journal.pone.0248427] [Reference Citation Analysis]
402 Frigstad SO, Høivik M, Jahnsen J, Dahl SR, Cvancarova M, Grimstad T, Berset IP, Huppertz-Hauss G, Hovde Ø, Torp R, Bernklev T, Moum B, Jelsness-Jørgensen LP. Vitamin D deficiency in inflammatory bowel disease: prevalence and predictors in a Norwegian outpatient population. Scand J Gastroenterol 2017;52:100-6. [PMID: 27603182 DOI: 10.1080/00365521.2016.1233577] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 11.0] [Reference Citation Analysis]
403 He Z, Zhou Q, Wen K, Wu B, Sun X, Wang X, Chen Y. Huangkui Lianchang Decoction Ameliorates DSS-Induced Ulcerative Colitis in Mice by Inhibiting the NF-kappaB Signaling Pathway. Evid Based Complement Alternat Med 2019;2019:1040847. [PMID: 31093294 DOI: 10.1155/2019/1040847] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
404 Grazie ML, Bagnoli S, Dragoni G, Caini S, Annese V, Innocenti T, Deiana S, Manetti N, Milani S, Galli A, Milla M. Infliximab is more effective than cyclosporine as a rescue therapy for acute severe ulcerative colitis: a retrospective single-center study. Ann Gastroenterol 2021;34:370-7. [PMID: 33948062 DOI: 10.20524/aog.2021.0584] [Reference Citation Analysis]
405 Carballal S, Maisterra S, López-serrano A, Gimeno-garcía AZ, Vera MI, Marín-garbriel JC, Díaz-tasende J, Márquez L, Álvarez MA, Hernández L, De Castro L, Gordillo J, Puig I, Vega P, Bustamante-balén M, Acevedo J, Peñas B, López-cerón M, Ricart E, Cuatrecasas M, Jimeno M, Pellisé M. Real-life chromoendoscopy for neoplasia detection and characterisation in long-standing IBD. Gut 2017;67:70-8. [DOI: 10.1136/gutjnl-2016-312332] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 13.2] [Reference Citation Analysis]
406 Mazzuoli S, Guglielmi FW, Antonelli E, Salemme M, Bassotti G, Villanacci V. Definition and evaluation of mucosal healing in clinical practice. Dig Liver Dis. 2013;45:969-977. [PMID: 23932331 DOI: 10.1016/j.dld.2013.06.010] [Cited by in Crossref: 73] [Cited by in F6Publishing: 57] [Article Influence: 9.1] [Reference Citation Analysis]
407 Del Hoyo J, Nos P, Faubel R, Muñoz D, Domínguez D, Bastida G, Valdivieso B, Correcher M, Aguas M. A Web-Based Telemanagement System for Improving Disease Activity and Quality of Life in Patients With Complex Inflammatory Bowel Disease: Pilot Randomized Controlled Trial. J Med Internet Res 2018;20:e11602. [PMID: 30482739 DOI: 10.2196/11602] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
408 Dai YC, Zhang YL, Wang LJ, Guo Q, Yang K, Ye RH, Tang ZP. Clinical presentation and treatment strategies for ulcerative colitis: A retrospective study of 247 inpatients. Chin J Integr Med. 2016;22:811-816. [PMID: 26501692 DOI: 10.1007/s11655-015-2118-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
409 Zittan E, Kelly OB, Kirsch R, Milgrom R, Burns J, Nguyen GC, Croitoru K, Van Assche G, Silverberg MS, Steinhart AH. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease. Inflamm Bowel Dis. 2016;22:623-630. [PMID: 26829408 DOI: 10.1097/mib.0000000000000652] [Cited by in Crossref: 93] [Cited by in F6Publishing: 35] [Article Influence: 18.6] [Reference Citation Analysis]
410 Christensen B, Hanauer SB, Erlich J, Kassim O, Gibson PR, Turner JR, Hart J, Rubin DT. Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes. Clin Gastroenterol Hepatol 2017; 15: 1557-1564. e1. [PMID: 28238954 DOI: 10.1016/j.cgh.2017.02.016] [Cited by in Crossref: 95] [Cited by in F6Publishing: 81] [Article Influence: 23.8] [Reference Citation Analysis]
411 Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, Kane SV, Sandborn WJ, Ullman TA, Moayyedi P. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011;106 Suppl 1:S2-S25; quiz S26. [PMID: 21472012 DOI: 10.1038/ajg.2011.58] [Cited by in Crossref: 177] [Cited by in F6Publishing: 164] [Article Influence: 17.7] [Reference Citation Analysis]
412 Moon JR, Lee CK, Hong SN, Im JP, Ye BD, Cha JM, Jung SA, Lee KM, Park DI, Jeen YT, Park YS, Cheon JH, Kim H, Seo B, Kim Y, Kim HJ; MOSAIK study group of the Korean Association for Study of Intestinal Diseases. Unmet Psychosocial Needs of Patients with Newly Diagnosed Ulcerative Colitis: Results from the Nationwide Prospective Cohort Study in Korea. Gut Liver 2020;14:459-67. [PMID: 31533398 DOI: 10.5009/gnl19107] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
413 Fernandes C, Allocca M, Danese S, Fiorino G. Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease. Immunotherapy 2015;7:175-90. [PMID: 25713992 DOI: 10.2217/imt.14.105] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
414 Atreya R, Peyrin-Biroulet L, Klymenko A, Augustyn M, Bakulin I, Slankamenac D, Miheller P, Gasbarrini A, Hébuterne X, Arnesson K, Knittel T, Kowalski J, Neurath MF, Sandborn WJ, Reinisch W; CONDUCT study group. Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial. Lancet Gastroenterol Hepatol 2020;5:1063-75. [PMID: 33031757 DOI: 10.1016/S2468-1253(20)30301-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
415 Timmer A, Preiss JC, Motschall E, Rücker G, Jantschek G, Moser G. Psychological interventions for treatment of inflammatory bowel disease. Cochrane Database Syst Rev 2011;:CD006913. [PMID: 21328288 DOI: 10.1002/14651858.CD006913.pub2] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 4.9] [Reference Citation Analysis]
416 Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lémann M, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, Bernhardt CA, Mary JY, Sandborn WJ. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012;61:535-42. [PMID: 21997563 DOI: 10.1136/gutjnl-2011-300486] [Cited by in Crossref: 295] [Cited by in F6Publishing: 250] [Article Influence: 29.5] [Reference Citation Analysis]
417 Magro F, Lopes S, Silva M, Coelho R, Portela F, Branquinho D, Correia L, Fernandes S, Cravo M, Caldeira P, Tavares de Sousa H, Patita M, Lago P, Ramos J, Afonso J, Redondo I, Machado P, Philip G, Lopes J, Carneiro F. Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab. Therap Adv Gastroenterol 2019;12:1756284819869141. [PMID: 31516554 DOI: 10.1177/1756284819869141] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
418 Alshehri D, Saadah O, Mosli M, Edris S, Alhindi R, Bahieldin A. Dysbiosis of gut microbiota in inflammatory bowel disease: Current therapies and potential for microbiota-modulating therapeutic approaches. Bosn J Basic Med Sci 2021;21:270-83. [PMID: 33052081 DOI: 10.17305/bjbms.2020.5016] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
419 Sandborn WJ, Targan SR, Byers VS, Rutty DA, Mu H, Zhang X, Tang T. Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. Am J Gastroenterol. 2013;108:90-98. [PMID: 23044768 DOI: 10.1038/ajg.2012.340] [Cited by in Crossref: 87] [Cited by in F6Publishing: 75] [Article Influence: 9.7] [Reference Citation Analysis]
420 Jackson B, De Cruz P. Algorithms to facilitate shared decision-making for the management of mild-to-moderate ulcerative colitis. Expert Rev Gastroenterol Hepatol 2018;12:1079-100. [PMID: 30284911 DOI: 10.1080/17474124.2018.1530109] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
421 Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W, Colombel JF, Vermeire S, Travis S, Lindsay JO, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965-990. [PMID: 23040452 DOI: 10.1016/j.crohns.2012.09.003] [Cited by in Crossref: 539] [Cited by in F6Publishing: 472] [Article Influence: 59.9] [Reference Citation Analysis]
422 Ardizzone S, Cassinotti A, de Franchis R. Immunosuppressive and biologic therapy for ulcerative colitis. Expert Opinion on Emerging Drugs 2012;17:449-67. [DOI: 10.1517/14728214.2012.744820] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
423 Abu-Sbeih H, Wang Y. Management Considerations for Immune Checkpoint Inhibitor-Induced Enterocolitis Based on Management of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2020;26:662-668. [PMID: 31560045 DOI: 10.1093/ibd/izz212] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
424 Adedokun OJ, Xu Z, Liao S, Strauss R, Reinisch W, Feagan BG, Sandborn WJ. Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis. Clin Ther 2020;42:157-174.e4. [PMID: 31982148 DOI: 10.1016/j.clinthera.2019.11.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
425 Caprilli R, Latella G, Frieri G. Treatment of inflammatory bowel diseases: to heal the wound or to heal the sick? J Crohns Colitis 2012;6:621-5. [PMID: 22425510 DOI: 10.1016/j.crohns.2012.02.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
426 Yamamoto-furusho J, Bozada-gutiérrez K, Sánchez-rodríguez A, Bojalil-romano F, Barreto-zuñiga R, Martínez-benitez B. Validación de un nuevo índice integral de enfermedad para evaluar el grado de actividad en pacientes mexicanos con colitis ulcerosa: un estudio de cohorte prospectivo. Revista de Gastroenterología de México 2019;84:317-25. [DOI: 10.1016/j.rgmx.2018.07.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
427 Frigstad SO, Høivik ML, Jahnsen J, Cvancarova M, Grimstad T, Berset IP, Huppertz-Hauss G, Hovde Ø, Bernklev T, Moum B, Jelsness-Jørgensen LP. Fatigue is not associated with vitamin D deficiency in inflammatory bowel disease patients. World J Gastroenterol 2018; 24(29): 3293-3301 [PMID: 30090009 DOI: 10.3748/wjg.v24.i29.3293] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
428 Shin J, Kong SM, Kim TJ, Kim ER, Hong SN, Chang DK, Kim YH. Clinical Significance of Residual Nonrectal Inflammation in Ulcerative Colitis Patients in Clinical Remission. Gut Liver 2021;15:401-9. [PMID: 32839361 DOI: 10.5009/gnl20078] [Reference Citation Analysis]
429 Lee JH, Cheon JH, Kim ES, Chung MJ, Kang W, Kim DH, Ha YJ, Park JJ, Kim TI, Kim WH. The prevalence and clinical significance of perinuclear anti-neutrophil cytoplasmic antibody in Korean patients with ulcerative colitis. Dig Dis Sci 2010;55:1406-12. [PMID: 19507028 DOI: 10.1007/s10620-009-0847-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
430 Melesse DY, Lix LM, Nugent Z, Targownik LE, Singh H, Blanchard JF, Bernstein CN. Estimates of Disease Course in Inflammatory Bowel Disease Using Administrative Data: A Population-level Study. J Crohns Colitis 2017;11:562-70. [PMID: 28453762 DOI: 10.1093/ecco-jcc/jjw201] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
431 Stremmel W, Braun A, Hanemann A, Ehehalt R, Autschbach F, Karner M. Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose finding study. J Clin Gastroenterol 2010;44:e101-7. [PMID: 20048683 DOI: 10.1097/MCG.0b013e3181c29860] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
432 徐斐, 刘菲. Chemerin和粪便钙卫蛋白对炎症性肠病活动性的诊断价值. 世界华人消化杂志 2017; 25(21): 1952-1958 [DOI: 10.11569/wcjd.v25.i21.1952] [Reference Citation Analysis]
433 Clark M, Colombel J, Feagan BC, Fedorak RN, Hanauer SB, Kamm MA, Mayer L, Regueiro C, Rutgeerts P, Sandborn WJ, Sands BE, Schreiber S, Targan S, Travis S, Vermeire S. American Gastroenterological Association Consensus Development Conference on the Use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21–23, 2006. Gastroenterology 2007;133:312-39. [DOI: 10.1053/j.gastro.2007.05.006] [Cited by in Crossref: 157] [Cited by in F6Publishing: 143] [Article Influence: 11.2] [Reference Citation Analysis]
434 Wei Y, Gong J, Zhu W, Tian H, Ding C, Gu L, Li N, Li J. Pectin enhances the effect of fecal microbiota transplantation in ulcerative colitis by delaying the loss of diversity of gut flora. BMC Microbiol 2016;16:255. [PMID: 27809778 DOI: 10.1186/s12866-016-0869-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
435 Irani NR, Wang LM, Collins GS, Keshav S, Travis SPL. Correlation Between Endoscopic and Histological Activity in Ulcerative Colitis Using Validated Indices. Journal of Crohn's and Colitis 2018;12:1151-7. [DOI: 10.1093/ecco-jcc/jjy081] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
436 Bálint A, Farkas K, Szepes Z, Nagy F, Szűcs M, Tiszlavicz L, Bor R, Milassin Á, Rutka M, Fábián A, Molnár T. How disease extent can be included in the endoscopic activity index of ulcerative colitis: the panMayo score, a promising scoring system. BMC Gastroenterol 2018;18:7. [PMID: 29310593 DOI: 10.1186/s12876-017-0725-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
437 Swanson GR, Sedghi S, Farhadi A, Keshavarzian A. Pattern of alcohol consumption and its effect on gastrointestinal symptoms in inflammatory bowel disease. Alcohol 2010;44:223-8. [PMID: 20682190 DOI: 10.1016/j.alcohol.2009.10.019] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 4.9] [Reference Citation Analysis]
438 Stidham RW, Cross RK. Endoscopy and cross-sectional imaging for assessing Crohn׳s disease activity. Tech Gastrointest Endosc 2016;18:123-30. [PMID: 28458507 DOI: 10.1016/j.tgie.2016.08.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
439 Huamán J, Casellas F, Borruel N, Peláez A, Torrejón A, Castells I, Masachs M, Varela E, Guarner F. Cutoff values of the Inflammatory Bowel Disease Questionnaire to predict a normal health related quality of life. Journal of Crohn's and Colitis 2010;4:637-41. [DOI: 10.1016/j.crohns.2010.07.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
440 Theede K, Holck S, Ibsen P, Kallemose T, Nordgaard-Lassen I, Nielsen AM. Fecal Calprotectin Predicts Relapse and Histological Mucosal Healing in Ulcerative Colitis. Inflamm Bowel Dis. 2016;22:1042-1048. [PMID: 26919460 DOI: 10.1097/mib.0000000000000736] [Cited by in Crossref: 77] [Cited by in F6Publishing: 23] [Article Influence: 19.3] [Reference Citation Analysis]
441 Spencer EA, Dubinsky MC. Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Pediatric Clinics of North America 2017;64:1309-26. [DOI: 10.1016/j.pcl.2017.08.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
442 Tanaka M, Nakanishi M, Miyazaki H, Morita R, Eguchi H, Takeda Y, Katayama M, Tanaka M, Bamba M, Shigematsu T. Granulocyte and Monocyte Adsorptive Apheresis for Ulcerative Colitis in a Patient with Low Bone Mineral Density Due to Fanconi-Bickel Syndrome. Intern Med 2021;60:2413-7. [PMID: 33612684 DOI: 10.2169/internalmedicine.6707-20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
443 Moran GW, Dubeau MF, Kaplan GG, Panaccione R, Ghosh S. Novel concepts in inflammatory bowel disease. British Medical Bulletin 2014;109:55-72. [DOI: 10.1093/bmb/ldt039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
444 Molander P, Färkkilä M, Salminen K, Kemppainen H, Blomster T, Koskela R, Jussila A, Rautiainen H, Nissinen M, Haapamäki J. Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission. Inflamm Bowel Dis. 2014;20:1021-1028. [PMID: 24798636 DOI: 10.1097/mib.0000000000000052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 20] [Article Influence: 0.9] [Reference Citation Analysis]
445 Sofia MA, Rubin DT. Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis. Therap Adv Gastroenterol 2016;9:548-59. [PMID: 27366223 DOI: 10.1177/1756283X16643242] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
446 Díaz-Jiménez D, De la Fuente M, Dubois-Camacho K, Landskron G, Fuentes J, Pérez T, González MJ, Simian D, Hermoso MA, Quera R. Soluble ST2 is a sensitive clinical marker of ulcerative colitis evolution. BMC Gastroenterol 2016;16:103. [PMID: 27565556 DOI: 10.1186/s12876-016-0520-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
447 Wohl P, Hucl T, Drastich P, Kamenar D, Spicak J, Honsova E, Sticova E, Lodererova A, Matous J, Hill M, Wohl P, Kucera M. Epithelial markers of colorectal carcinogenesis in ulcerative colitis and primary sclerosing cholangitis. World J Gastroenterol 2013; 19(14): 2234-2241 [PMID: 23599650 DOI: 10.3748/wjg.v19.i14.2234] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
448 Ma HQ, Yu TT, Zhao XJ, Zhang Y, Zhang HJ. Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease. World J Gastroenterol 2018; 24(13): 1464-1477 [PMID: 29632427 DOI: 10.3748/wjg.v24.i13.1464] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 24] [Article Influence: 9.7] [Reference Citation Analysis]
449 Chang JY, Cheon JH, Park Y, Park SJ, Kim TI, Kim WH. Does Medical Acceleration Improve Outcomes in Ulcerative Colitis Patients Who Are in Clinical Remission but Have Endoscopic Inflammation? Dig Dis Sci 2018;63:3041-8. [PMID: 29987626 DOI: 10.1007/s10620-018-5193-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
450 Orchard TR, van der Geest SA, Travis SP. Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis-new light on a familiar question. Aliment Pharmacol Ther. 2011;33:1028-1035. [PMID: 21385195 DOI: 10.1111/j.1365-2036.2011.04620.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
451 Jeon HH, Lee HJ, Jang HW, Yoon JY, Jung YS, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Clinical outcomes and predictive factors in oral corticosteroid-refractory active ulcerative colitis. World J Gastroenterol 2013; 19(2): 265-273 [PMID: 23345950 DOI: 10.3748/wjg.v19.i2.265] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
452 Chandan S, Mohan BP, Chandan OC, Ahmad R, Challa A, Tummala H, Singh S, Dhawan P, Ponnada S, Singh AB, Adler DG. Curcumin use in ulcerative colitis: is it ready for prime time? A systematic review and meta-analysis of clinical trials. Ann Gastroenterol 2020;33:53-8. [PMID: 31892798 DOI: 10.20524/aog.2019.0439] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
453 Guirgis M, Wendt E, Wang LM, Walsh A, Burger D, Bryant RV, Kent A, Adamson R, Brain O, Travis SPL, Keshav S. Beyond Histological Remission: Intramucosal Calprotectin as a Potential Predictor of Outcomes in Ulcerative Colitis. ECCOJC. [DOI: 10.1093/ecco-jcc/jjw174] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
454 Takenaka K, Tominaga K, Kanazawa M, Fukushi K, Tanaka T, Kanamori A, Sugaya T, Tsuchida K, Iijima M, Goda K, Irisawa A. Endoscopic score vs blood cell indices for determining timing of immunomodulator withdrawal in quiescent ulcerative colitis. Sci Rep 2019;9:17751. [PMID: 31780764 DOI: 10.1038/s41598-019-54369-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
455 Ishida N, Tamura S, Miyazu T, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Comparison between Prostaglandin E-major urinary metabolite and C-reactive protein levels to reflect endoscopic scores in patients with ulcerative colitis. Sci Rep 2021;11:16205. [PMID: 34376764 DOI: 10.1038/s41598-021-95761-6] [Reference Citation Analysis]
456 Celikbilek A, Celikbilek M, Sabah S, Tanık N, Borekci E, Dogan S, Akin Y, Baldane S, Deniz K, Yilmaz N. The Serum S100B Level as a Biomarker of Enteroglial Activation in Patients with Ulcerative Colitis. Int J Inflam. 2014;2014:986525. [PMID: 24790767 DOI: 10.1155/2014/986525] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
457 Casellas F, Barreiro de Acosta M, Iglesias M, Robles V, Nos P, Aguas M, Riestra S, de Francisco R, Papo M, Borruel N. Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2012;24:762-769. [PMID: 22517240 DOI: 10.1097/meg.0b013e32835414b2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
458 Römkens TE, Kampschreur MT, Drenth JP, van Oijen MG, de Jong DJ. High mucosal healing rates in 5-ASA-treated ulcerative colitis patients: Results of a meta-analysis of clinical trials: . Inflammatory Bowel Diseases 2012;18:2190-8. [DOI: 10.1002/ibd.22939] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
459 Ponte A, Pinho R, Fernandes S, Rodrigues A, Alberto L, Silva JC, Silva J, Rodrigues J, Sousa M, Silva AP, Proença L, Freitas T, Leite S, Carvalho J. Impact of Histological and Endoscopic Remissions on Clinical Recurrence and Recurrence-free Time in Ulcerative Colitis. Inflamm Bowel Dis 2017;23:2238-44. [PMID: 28991857 DOI: 10.1097/MIB.0000000000001275] [Cited by in Crossref: 26] [Cited by in F6Publishing: 5] [Article Influence: 8.7] [Reference Citation Analysis]
460 Scoville EA, Schwartz DA. Endoscopy in inflammatory bowel disease: advances in disease management. Gastrointest Endosc 2017;86:952-61. [PMID: 28886962 DOI: 10.1016/j.gie.2017.08.034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
461 Vilela EG, Torres HODG, Martins FP, Ferrari MLA, Andrade MM, Cunha ASD. Evaluation of inflammatory activity in Crohn’s disease and ulcerative colitis. World J Gastroenterol 2012; 18(9): 872-881 [PMID: 22408345 DOI: 10.3748/wjg.v18.i9.872] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 51] [Article Influence: 6.2] [Reference Citation Analysis]
462 Tan Y, Guan Y, Sun Y, Zheng C. Correlation of Intestinal Mucosal Healing and Tight Junction Protein Expression in Ulcerative Colitis Patients. Am J Med Sci. 2019;357:195-204. [PMID: 30638599 DOI: 10.1016/j.amjms.2018.11.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
463 Lee CK, Lee KM, Park DI, Jung SA, Jeen YT, Park YS, Kim HJ; MOSAIK study group of the Korean Association for the Study of Intestinal Diseases (KASID). A new opportunity for innovative inflammatory bowel disease research: the moderate-to-severe ulcerative colitis in Korea (MOSAIK) cohort study. Intest Res 2019;17:1-5. [PMID: 30678443 DOI: 10.5217/ir.2019.00005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
464 Dhanda AD, Creed TJ, Greenwood R, Sands BE, Probert CS. Can endoscopy be avoided in the assessment of ulcerative colitis in clinical trials?: . Inflammatory Bowel Diseases 2012;18:2056-62. [DOI: 10.1002/ibd.22879] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
465 Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther. 2010;31:693-707. [PMID: 20064142 DOI: 10.1111/j.1365-2036.2010.04234.x] [Cited by in Crossref: 141] [Cited by in F6Publishing: 135] [Article Influence: 12.8] [Reference Citation Analysis]
466 Ivanova A, Tamura RN. A two-way enriched clinical trial design: combining advantages of placebo lead-in and randomized withdrawal. Stat Methods Med Res 2015;24:871-90. [DOI: 10.1177/0962280211431023] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
467 Wildt S, Nordgaard I, Hansen U, Brockmann E, Rumessen JJ. A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. J Crohns Colitis. 2011;5:115-121. [PMID: 21453880 DOI: 10.1016/j.crohns.2010.11.004] [Cited by in Crossref: 83] [Cited by in F6Publishing: 72] [Article Influence: 8.3] [Reference Citation Analysis]
468 Suzuki Y, Uchiyama K, Kato M, Matsuo K, Nakagawa T, Kishikawa H, Kimura N, Kasanuki J, Ino S. Potential utility of a new ulcerative colitis segmental endoscopic index combining disease severity and the extent of inflammation. J Clin Gastroenterol 2015;49:401-6. [PMID: 25127112 DOI: 10.1097/MCG.0000000000000199] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
469 Pearl DS, Masoodi M, Eiden M, Brümmer J, Gullick D, McKeever TM, Whittaker MA, Nitch-Smith H, Brown JF, Shute JK. Altered colonic mucosal availability of n-3 and n-6 polyunsaturated fatty acids in ulcerative colitis and the relationship to disease activity. J Crohns Colitis. 2014;8:70-79. [PMID: 23619007 DOI: 10.1016/j.crohns.2013.03.013] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
470 Bastida G, Herrera-de Guise C, Algaba A, Ber Nieto Y, Soares JM, Robles V, Bermejo F, Sáez-González E, Gomollón F, Nos P. Sucrosomial Iron Supplementation for the Treatment of Iron Deficiency Anemia in Inflammatory Bowel Disease Patients Refractory to Oral Iron Treatment. Nutrients 2021;13:1770. [PMID: 34067320 DOI: 10.3390/nu13061770] [Reference Citation Analysis]
471 Turner D, Griffiths AM, Mack D, Otley AR, Seow CH, Steinhart HA, Silverberg MS, Hyams J, Guyatt GH. Assessing disease activity in ulcerative colitis: Patients or their physicians? Inflammatory Bowel Diseases 2010;16:651-6. [DOI: 10.1002/ibd.21088] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
472 Villanacci V, Antonelli E, Geboes K, Casella G, Bassotti G. Histological healing in inflammatory bowel disease: A still unfulfilled promise. World J Gastroenterol 2013; 19(7): 968-978 [PMID: 23467585 DOI: 10.3748/wjg.v19.i7.968] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 54] [Article Influence: 7.1] [Reference Citation Analysis]
473 Buda A, Hatem G, Neumann H, D' Incà R, Mescoli C, Piselli P, Jackson J, Bruno M, Sturniolo GC. Confocal laser endomicroscopy for prediction of disease relapse in ulcerative colitis: A pilot study. Journal of Crohn's and Colitis 2014;8:304-11. [DOI: 10.1016/j.crohns.2013.09.005] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 6.6] [Reference Citation Analysis]
474 Puolanne AM, Kolho KL, Alfthan H, Ristimäki A, Mustonen H, Färkkilä M. Rapid faecal tests for detecting disease activity in colonic inflammatory bowel disease. Eur J Clin Invest 2016;46:825-32. [PMID: 27438629 DOI: 10.1111/eci.12660] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
475 Panaccione R, Rutgeerts P, Sandborn WJ, Feagan B, Schreiber S, Ghosh S. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28:674-688. [PMID: 18532990 DOI: 10.1111/j.1365-2036.2008.03753.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 5.3] [Reference Citation Analysis]
476 Pai RK, Hartman DJ, Rivers CR, Regueiro M, Schwartz M, Binion DG, Pai RK. Complete Resolution of Mucosal Neutrophils Associates With Improved Long-Term Clinical Outcomes of Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2020;18:2510-2517.e5. [DOI: 10.1016/j.cgh.2019.12.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
477 Bitton A, Buie D, Enns R, Feagan BG, Jones JL, Marshall JK, Whittaker S, Griffiths AM, Panaccione R; Canadian Association of Gastroenterology Severe Ulcerative Colitis Consensus Group. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol. 2012;107:179-194; author reply 195. [PMID: 22108451 DOI: 10.1038/ajg.2011.386] [Cited by in Crossref: 106] [Cited by in F6Publishing: 92] [Article Influence: 10.6] [Reference Citation Analysis]
478 Kim ES, Kim KO, Jang BI, Kim EY, Lee YJ, Lee HS, Jeon SW, Kim HJ, Kim SK; Crohn’s and Colitis Association in Daegu-Gyeongbuk (CCAiD). Comparison of 4-L Polyethylene Glycol and 2-L Polyethylene Glycol Plus Ascorbic Acid in Patients with Inactive Ulcerative Colitis. Dig Dis Sci 2017;62:2489-97. [PMID: 28639128 DOI: 10.1007/s10620-017-4634-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
479 Ma R, Meng R, Zhang X, Sun Z, Lei Y. Correlation between fecal calprotectin, ulcerative colitis endoscopic index of severity and clinical outcome in patients with acute severe colitis. Exp Ther Med 2020;20:1498-504. [PMID: 32765673 DOI: 10.3892/etm.2020.8861] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
480 Lakatos G, Hritz I, Varga MZ, Juhász M, Miheller P, Cierny G, Tulassay Z, Herszényi L. The impact of matrix metalloproteinases and their tissue inhibitors in inflammatory bowel diseases. Dig Dis. 2012;30:289-295. [PMID: 22722554 DOI: 10.1159/000336995] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 6.4] [Reference Citation Analysis]
481 Lan A, Blachier F, Benamouzig R, Beaumont M, Barrat C, Coelho D, Lancha A Jr, Kong X, Yin Y, Marie JC, Tomé D. Mucosal healing in inflammatory bowel diseases: is there a place for nutritional supplementation? Inflamm Bowel Dis 2015;21:198-207. [PMID: 25208104 DOI: 10.1097/MIB.0000000000000177] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
482 Bernstein CN. Spicing up the Treatment of Mild to Moderate Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2015;13:1450-2. [DOI: 10.1016/j.cgh.2015.04.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
483 Yamamoto T, Shimoyama T, Umegae S, Matsumoto K. Endoscopic score vs. fecal biomarkers for predicting relapse in patients with ulcerative colitis after clinical remission and mucosal healing. Clin Transl Gastroenterol 2018;9:136. [PMID: 29491393 DOI: 10.1038/s41424-018-0006-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
484 Papi C, Aratari A. Mucosal healing as a treatment for IBD? Expert Review of Gastroenterology & Hepatology 2014;8:457-9. [DOI: 10.1586/17474124.2014.902302] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
485 Moriichi K, Fujiya M, Ijiri M, Tanaka K, Sakatani A, Dokoshi T, Fujibayashi S, Ando K, Nomura Y, Ueno N. Quantification of autofluorescence imaging can accurately and objectively assess the severity of ulcerative colitis. Int J Colorectal Dis. 2015;30:1639-1643. [PMID: 26264047 DOI: 10.1007/s00384-015-2332-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
486 Yoon JY, Cha JM, Lee CK, Park YS, Huh KC, Shin JE, Kim YS, Eun CS, Yoon SM, Cheon JH, Park YS, Ye BD, Lee Y, Kim Y, Kim HJ; MOSAIK study group of the Korean Association for the Study of Intestinal Diseases (KASID). Early course of newly diagnosed moderate-to-severe ulcerative colitis in Korea: Results from a hospital-based inception cohort study (MOSAIK). J Gastroenterol Hepatol 2021;36:2149-56. [PMID: 33555067 DOI: 10.1111/jgh.15435] [Reference Citation Analysis]
487 Freeman HJ. Limitations in assessment of mucosal healing in inflammatory bowel disease. World J Gastroenterol 2010; 16(1): 15-20 [PMID: 20039444 DOI: 10.3748/wjg.v16.i1.15] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
488 Tandon P, Lee EY, Maxwell C, Hitz L, Ambrosio L, Dieleman L, Halloran B, Kroeker K, Huang VM. Fecal Calprotectin May Predict Adverse Pregnancy-Related Outcomes in Patients with Inflammatory Bowel Disease. Dig Dis Sci 2021;66:1639-49. [PMID: 32533542 DOI: 10.1007/s10620-020-06381-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
489 Molander P, Sipponen T, Kemppainen H, Jussila A, Blomster T, Koskela R, Nissinen M, Rautiainen H, Kuisma J, Kolho K, Färkkilä M. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD. Journal of Crohn's and Colitis 2013;7:730-5. [DOI: 10.1016/j.crohns.2012.10.018] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 9.1] [Reference Citation Analysis]
490 Pena-Rossi C, Schreiber S, Golubovic G, Mertz-Nielsen A, Panes J, Rachmilewitz D, Shieh MJ, Simanenkov VI, Stanton D, Graffner H. Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-la in moderately active ulcerative colitis. Aliment Pharmacol Ther. 2008;28:758-767. [PMID: 19145731 DOI: 10.1111/j.1365-2036.2008.03778.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
491 Rutgeerts P, Feagan BG, Marano CW, Padgett L, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Zhang H, Colombel JF. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis. Aliment Pharmacol Ther. 2015;42:504-514. [PMID: 26119226 DOI: 10.1111/apt.13291] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 7.7] [Reference Citation Analysis]
492 Baumgart DC. The diagnosis and treatment of Crohn's disease and ulcerative colitis. Dtsch Arztebl Int. 2009;106:123-133. [PMID: 19568370 DOI: 10.3238/arztebl.2009.0123] [Cited by in Crossref: 11] [Cited by in F6Publishing: 24] [Article Influence: 0.9] [Reference Citation Analysis]
493 Thia KT, Loftus EV, Pardi DS, Kane SV, Faubion WA, Tremaine WJ, Schroeder KW, Harmsen SW, Zinsmeister AR, Sandborn WJ. Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity. Inflamm Bowel Dis. 2011;17:1257-1264. [PMID: 20878712 DOI: 10.1002/ibd.21480] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
494 Carlsen K, Riis LB, Elsberg H, Maagaard L, Thorkilgaard T, Sørbye SW, Jakobsen C, Wewer V, Florholmen J, Goll R, Munkholm P. The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis. Scand J Gastroenterol 2018;53:825-30. [PMID: 29968483 DOI: 10.1080/00365521.2018.1482956] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
495 Greenberg S, Herfarth HH, Barnes EL. Predictors of Inadequate Response to Budesonide Multimatrix in Real-World Patients with Ulcerative Colitis. Inflamm Intest Dis 2019;4:115-22. [PMID: 31559263 DOI: 10.1159/000501004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
496 Kristensen V, Lauritzen T, Jelsness-Jørgensen LP, Frigstad SO, Corwin C, Moum B. Patient-performed extraction of faecal calprotectin. Clin Chem Lab Med 2016;54:1357-63. [PMID: 26812797 DOI: 10.1515/cclm-2015-1037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
497 Soltys K, Stuchlikova M, Hlavaty T, Gaalova B, Budis J, Gazdarica J, Krajcovicova A, Zelinkova Z, Szemes T, Kuba D, Drahovska H, Turna J, Stuchlik S. Seasonal changes of circulating 25-hydroxyvitamin D correlate with the lower gut microbiome composition in inflammatory bowel disease patients. Sci Rep 2020;10:6024. [PMID: 32265456 DOI: 10.1038/s41598-020-62811-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
498 Han W, Xu J, Hu N, Mei Q, Liu M. Early predictors of responses and clinical outcomes of corticosteroid treatment for severe ulcerative colitis. Scandinavian Journal of Gastroenterology 2014;49:424-33. [DOI: 10.3109/00365521.2014.886716] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
499 Chevaux JB, Vavricka SR, Rogler G, Lakatos PL, Schoepfer A, Peyrin-Biroulet L. Mucosal healing with anti-TNF antibodies. Digestion. 2012;86 Suppl 1:16-22. [PMID: 23051722 DOI: 10.1159/000341957] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
500 Opheim R, Fagermoen MS, Bernklev T, Jelsness-Jorgensen LP, Moum B. Fatigue interference with daily living among patients with inflammatory bowel disease. Qual Life Res 2014;23:707-17. [PMID: 23975381 DOI: 10.1007/s11136-013-0508-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
501 Samuel S, Bruining DH, Loftus EV, Thia KT, Schroeder KW, Tremaine WJ, Faubion WA, Kane SV, Pardi DS, de Groen PC, Harmsen WS, Zinsmeister AR, Sandborn WJ. Validation of the Ulcerative Colitis Colonoscopic Index of Severity and Its Correlation With Disease Activity Measures. Clinical Gastroenterology and Hepatology 2013;11:49-54.e1. [DOI: 10.1016/j.cgh.2012.08.003] [Cited by in Crossref: 87] [Cited by in F6Publishing: 71] [Article Influence: 10.9] [Reference Citation Analysis]
502 Cheng YW, Fischer M. Fecal Microbiota Transplantation for Ulcerative Colitis. Are We Ready for Primetime? Gastroenterol Clin North Am 2020;49:739-52. [PMID: 33121693 DOI: 10.1016/j.gtc.2020.08.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
503 Toyonaga T, Kobayashi T, Nakano M, Saito E, Umeda S, Okabayashi S, Ozaki R, Hibi T. Usefulness of fecal calprotectin for the early prediction of short-term outcomes of remission-induction treatments in ulcerative colitis in comparison with two-item patient-reported outcome. PLoS One 2017;12:e0185131. [PMID: 28934315 DOI: 10.1371/journal.pone.0185131] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
504 Bhambhvani HP, Zamora A. Deep learning enabled classification of Mayo endoscopic subscore in patients with ulcerative colitis. Eur J Gastroenterol Hepatol. 2021;33:645-649. [PMID: 33079775 DOI: 10.1097/meg.0000000000001952] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
505 Masclee GM, Penders J, Pierik M, Wolffs P, Jonkers D. Enteropathogenic viruses: triggers for exacerbation in IBD? A prospective cohort study using real-time quantitative polymerase chain reaction. Inflamm Bowel Dis 2013;19:124-31. [PMID: 22508685 DOI: 10.1002/ibd.22976] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
506 Bager P, Befrits R, Wikman O, Lindgren S, Moum B, Hjortswang H, Hjollund NH, Dahlerup JF. Fatigue in out-patients with inflammatory bowel disease is common and multifactorial. Aliment Pharmacol Ther. 2012;35:133-141. [PMID: 22059387 DOI: 10.1111/j.1365-2036.2011.04914.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 6.4] [Reference Citation Analysis]
507 Keohane J, O’Mahony C, O’Mahony L, O’Mahony S, Quigley EM, Shanahan F. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J Gastroenterol. 2010;105:1788, 1789-1794; quiz 1795. [PMID: 20389294 DOI: 10.1038/ajg.2010.156] [Cited by in Crossref: 129] [Cited by in F6Publishing: 152] [Article Influence: 11.7] [Reference Citation Analysis]
508 Zhang Y, Chen D, Wang F, Li X, Xue X, Jiang M, Xu B, Chu Y, Wang W, Wu K, Mao R, Shen J, Yang S, Liang J. Comparison of the efficiency of different enemas on patients with distal ulcerative colitis. Cell Prolif 2019;52:e12559. [PMID: 30659678 DOI: 10.1111/cpr.12559] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
509 Zhang Q, Travis J, Rothwell R, Jay CE, Jahidur R, Zhang Y, Crentsil V, Altepeter T, Lee JJ, Burckart GJ, Ganley C, Wang J. Applying the Noninferiority Paradigm to Assess Exposure-Response Similarity and Dose Between Pediatric and Adult Patients. J Clin Pharmacol 2021;61 Suppl 1:S165-74. [PMID: 34185895 DOI: 10.1002/jcph.1885] [Reference Citation Analysis]
510 Ikeya K, Hanai H, Sugimoto K, Osawa S, Kawasaki S, Iida T, Maruyama Y, Watanabe F. The Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic Score. J Crohns Colitis. 2016;10:286-295. [PMID: 26581895 DOI: 10.1093/ecco-jcc/jjv210] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 10.7] [Reference Citation Analysis]
511 Magro F, Lopes SI, Lopes J, Portela F, Cotter J, Lopes S, Moreira MJ, Lago P, Peixe P, Albuquerque A, Rodrigues S, Silva MR, Monteiro P, Lopes C, Monteiro L, Macedo G, Veloso L, Camila C, Afonso J, Geboes K, Carneiro F; Portuguese IBD group [GEDII]. Histological Outcomes and Predictive Value of Faecal Markers in Moderately to Severely Active Ulcerative Colitis Patients Receiving Infliximab. J Crohns Colitis 2016;10:1407-16. [PMID: 27226417 DOI: 10.1093/ecco-jcc/jjw112] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
512 Naganuma M, Ichikawa H, Inoue N, Kobayashi T, Okamoto S, Hisamatsu T, Kanai T, Ogata H, Iwao Y, Hibi T. Novel endoscopic activity index is useful for choosing treatment in severe active ulcerative colitis patients. J Gastroenterol 2010;45:936-43. [DOI: 10.1007/s00535-010-0244-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
513 Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K, Joseph R. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2009;15:1-8. [PMID: 18671232 DOI: 10.1002/ibd.20580] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 5.1] [Reference Citation Analysis]
514 Palmela C, Torres J, Cravo M. New Trends in Inflammatory Bowel Disease. GE Port J Gastroenterol 2015;22:103-11. [PMID: 28868386 DOI: 10.1016/j.jpge.2015.03.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
515 Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association. Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing). J Dig Dis 2021;22:298-317. [PMID: 33905603 DOI: 10.1111/1751-2980.12994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
516 Sandborn WJ. Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations? J Clin Gastroenterol 2008;42:338-44. [PMID: 18277908 DOI: 10.1097/MCG.0b013e3181595b56] [Cited by in Crossref: 23] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
517 Reinisch W, Colombel J, Gibson PR, Rutgeerts P, Sandborn WJ, Tarabar D, Huyck S, Khalifa A, Marano C, Philip G, Yao R, Zhang H, Cornillie F. Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab. Inflammatory Bowel Diseases 2019;25:163-71. [DOI: 10.1093/ibd/izy229] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
518 Dulai PS, Singh S, Casteele NV, Boland BS, Sandborn WJ. How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease. Inflamm Bowel Dis 2016;22:998-1009. [PMID: 26835982 DOI: 10.1097/MIB.0000000000000661] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
519 Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:85-95; quiz e14-15. [PMID: 23735746 DOI: 10.1053/j.gastro.2013.05.048] [Cited by in Crossref: 480] [Cited by in F6Publishing: 433] [Article Influence: 60.0] [Reference Citation Analysis]
520 Aghdaei HA, Kadijani AA, Sorrentino D, Mirzaei A, Shahrokh S, Balaii H, Geraci M, Zali MR. An increased Bax/Bcl-2 ratio in circulating inflammatory cells predicts primary response to infliximab in inflammatory bowel disease patients. United European Gastroenterol J. 2018;6:1074-1081. [PMID: 30228896 DOI: 10.1177/2050640618774637] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
521 Tyler CJ, Pérez-Jeldres T, Ehinger E, Capaldo B, Karuppuchamy T, Boyer JD, Patel D, Dulai P, Boland BS, Lannigan J, Eckmann L, Ernst PB, Sandborn WJ, Ho SB, Rivera-Nieves J. Implementation of Mass Cytometry as a Tool for Mechanism of Action Studies in Inflammatory Bowel Disease. Inflamm Bowel Dis 2018;24:2366-76. [PMID: 29889233 DOI: 10.1093/ibd/izy214] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
522 Panés J, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, Zhang H, Yarlas A, Bayliss M, Maher S, Cappelleri JC, Bushmakin AG, Rubin DT. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. J Crohns Colitis 2018;12:145-56. [PMID: 29028981 DOI: 10.1093/ecco-jcc/jjx133] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 15.0] [Reference Citation Analysis]
523 Trejo-Vazquez F, Garza-Veloz I, Villela-Ramirez GA, Ortiz-Castro Y, Mauricio-Saucedo P, Cardenas-Vargas E, Diaz-Baez M, Cid-Baez MA, Castañeda-Miranda R, Ortiz-Rodriguez JM, Solis-Sanchez LO, Martinez-Fierro ML. Positive association between leptin serum levels and disease activity on endoscopy in inflammatory bowel disease: A case-control study. Exp Ther Med 2018;15:3336-44. [PMID: 29545852 DOI: 10.3892/etm.2018.5835] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
524 Tursi A, Elisei W, Picchio M, Forti G, Penna A, Inchingolo CD, Nenna R, Brandimarte G. Histological inflammation in ulcerative colitis in deep remission under treatment with infliximab. Clin Res Hepatol Gastroenterol. 2015;39:107-113. [PMID: 25176588 DOI: 10.1016/j.clinre.2014.07.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
525 Pugliese D, Aratari A, Festa S, Ferraro PM, Monterubbianesi R, Guidi L, Scribano ML, Papi C, Armuzzi A. Sustained Clinical Efficacy and Mucosal Healing of Thiopurine Maintenance Treatment in Ulcerative Colitis: A Real-Life Study. Gastroenterol Res Pract 2018;2018:4195968. [PMID: 30402090 DOI: 10.1155/2018/4195968] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
526 Mohammed N, Subramanian V. Clinical relevance of endoscopic assessment of inflammation in ulcerative colitis: Can endoscopic evaluation predict outcomes? World J Gastroenterol 2016; 22(42): 9324-9332 [PMID: 27895420 DOI: 10.3748/wjg.v22.i42.9324] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
527 Ma C, Guizzetti L, Panaccione R, Fedorak RN, Pai RK, Parker CE, Nguyen TM, Khanna R, Vande Casteele N, D'Haens G, Sandborn WJ, Feagan BG, Jairath V. Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. Aliment Pharmacol Ther 2018;47:1578-96. [PMID: 29696670 DOI: 10.1111/apt.14672] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
528 Zhang W, Teng G, Wu T, Tian Y, Wang H. Expression and Clinical Significance of Elafin in Inflammatory Bowel Disease. Inflamm Bowel Dis 2017;23:2134-41. [PMID: 29084078 DOI: 10.1097/MIB.0000000000001252] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
529 Boal Carvalho P, Dias de Castro F, Rosa B, Moreira MJ, Cotter J. Mucosal Healing in Ulcerative Colitis--When Zero is Better. J Crohns Colitis. 2016;10:20-25. [PMID: 26438714 DOI: 10.1093/ecco-jcc/jjv180] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
530 Narang V, Kaur R, Garg B, Mahajan R, Midha V, Sood N, Sood A. Association of endoscopic and histological remission with clinical course in patients of ulcerative colitis. Intest Res. 2018;16:55-61. [PMID: 29422798 DOI: 10.5217/ir.2018.16.1.55] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 10.7] [Reference Citation Analysis]
531 Ventham NT, Kalla R, Kennedy NA, Satsangi J, Arnott ID. Predicting outcomes in acute severe ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2015;9:405-415. [PMID: 25494666 DOI: 10.1586/17474124.2015.992880] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
532 Bryant RV, Burger DC, Delo J, Walsh AJ, Thomas S, von Herbay A, Buchel OC, White L, Brain O, Keshav S, Warren BF, Travis SP. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut. 2016;65:408-414. [PMID: 25986946 DOI: 10.1136/gutjnl-2015-309598] [Cited by in Crossref: 190] [Cited by in F6Publishing: 170] [Article Influence: 31.7] [Reference Citation Analysis]
533 Kedia S, Ahuja V, Tandon R. Management of acute severe ulcerative colitis. World J Gastrointest Pathophysiol 2014; 5(4): 579-588 [PMID: 25401001 DOI: 10.4291/wjgp.v5.i4.579] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
534 Pittet VEH, Maillard MH, Simonson T, Fournier N, Rogler G, Michetti P; Swiss IBD Cohort Study Group(∗). Differences in Outcomes Reported by Patients With Inflammatory Bowel Diseases vs Their Health Care Professionals. Clin Gastroenterol Hepatol 2019;17:2050-2059.e1. [PMID: 30471455 DOI: 10.1016/j.cgh.2018.11.029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
535 Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, Armstrong D, Marshall JK, Kassam Z, Reinisch W, Lee CH. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology. 2015;149:102-109.e6. [PMID: 25857665 DOI: 10.1053/j.gastro.2015.04.001] [Cited by in Crossref: 733] [Cited by in F6Publishing: 637] [Article Influence: 122.2] [Reference Citation Analysis]
536 Yılmaz B, Köklü S, Yüksel O, Arslan S. Serum beta 2-microglobulin as a biomarker in inflammatory bowel disease. World J Gastroenterol 2014; 20(31): 10916-10920 [PMID: 25152594 DOI: 10.3748/wjg.v20.i31.10916] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
537 Bryant RV, Brain O, Travis SP. Conventional drug therapy for inflammatory bowel disease. Scand J Gastroenterol. 2015;50:90-112. [PMID: 25523560 DOI: 10.3109/00365521.2014.968864] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 6.7] [Reference Citation Analysis]
538 Peyrin-biroulet L, Lémann M. Review article: remission rates achievable by current therapies for inflammatory bowel disease: Review: remission rates in IBD. Alimentary Pharmacology & Therapeutics 2011;33:870-9. [DOI: 10.1111/j.1365-2036.2011.04599.x] [Cited by in Crossref: 105] [Cited by in F6Publishing: 90] [Article Influence: 10.5] [Reference Citation Analysis]
539 Pineton de Chambrun G, Blanc P, Peyrin-biroulet L. Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology 2016. [DOI: 10.1586/17474124.2016.1174064] [Cited by in Crossref: 14] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
540 Julsgaard M, Hvas CL, Gearry RB, Vestergaard T, Fallingborg J, Svenningsen L, Kjeldsen J, Sparrow MP, Wildt S, Kelsen J, Bell SJ. Fecal Calprotectin Is Not Affected by Pregnancy: Clinical Implications for the Management of Pregnant Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2017;23:1240-6. [DOI: 10.1097/mib.0000000000001136] [Cited by in Crossref: 31] [Cited by in F6Publishing: 9] [Article Influence: 7.8] [Reference Citation Analysis]
541 Murthy SK, Shukla T, Antonova L, Belair MA, Ramsay T, Gallinger Z, Nguyen GC, Benchimol EI. Predictive models of disease burden at diagnosis in persons with adult-onset ulcerative colitis using health administrative data. BMC Gastroenterol 2019;19:13. [PMID: 30665357 DOI: 10.1186/s12876-018-0924-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
542 Yamamoto-furusho J, Bosques-padilla F, de-Paula J, Galiano M, Ibañez P, Juliao F, Kotze P, Rocha J, Steinwurz F, Veitia G, Zaltman C. Diagnóstico y tratamiento de la enfermedad inflamatoria intestinal: Primer Consenso Latinoamericano de la Pan American Crohn's and Colitis Organisation. Revista de Gastroenterología de México 2017;82:46-84. [DOI: 10.1016/j.rgmx.2016.07.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
543 Jitsumura M, Kokelaar RF, Harris DA. Remission endpoints in ulcerative colitis: A systematic review. World J Meta-Anal 2017; 5(4): 85-102 [DOI: 10.13105/wjma.v5.i4.85] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
544 Dryahina K, Španěl P, Pospíšilová V, Sovová K, Hrdlička L, Machková N, Lukáš M, Smith D. Quantification of pentane in exhaled breath, a potential biomarker of bowel disease, using selected ion flow tube mass spectrometry. Rapid Commun Mass Spectrom 2013;27:1983-92. [PMID: 23939966 DOI: 10.1002/rcm.6660] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 7.1] [Reference Citation Analysis]
545 Spagnuolo R, Montalcini T, De Bonis D, Ferro Y, Cosco C, Mazza E, Romeo S, Doldo P, Pujia A. Weight Gain and Liver Steatosis in Patients with Inflammatory Bowel Diseases. Nutrients 2019;11:E303. [PMID: 30717085 DOI: 10.3390/nu11020303] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
546 Vande Casteele N, Jeyarajah J, Jairath V, Feagan BG, Sandborn WJ. Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2019;17:1814-1821.e1. [DOI: 10.1016/j.cgh.2018.10.036] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
547 Joseph NE, Weber CR. Pathology of Inflammatory Bowel Disease. In: Baumgart DC, editor. Crohn's Disease and Ulcerative Colitis. Cham: Springer International Publishing; 2017. pp. 243-58. [DOI: 10.1007/978-3-319-33703-6_22] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
548 Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L, Hibi T. Ulcerative colitis.Nat Rev Dis Primers. 2020;6:74. [PMID: 32913180 DOI: 10.1038/s41572-020-0205-x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 52.0] [Reference Citation Analysis]
549 Yim SM, Kim DH, Lee HJ, Jang HW, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Mucosal healing predicts the long-term prognosis of intestinal Behçet's disease. Dig Dis Sci 2014;59:2529-35. [PMID: 24838499 DOI: 10.1007/s10620-014-3198-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
550 Jürgens M, Laubender RP, Hartl F, Weidinger M, Seiderer J, Wagner J, Wetzke M, Beigel F, Pfennig S, Stallhofer J. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol. 2010;105:1811-1819. [PMID: 20197757 DOI: 10.1038/ajg.2010.95] [Cited by in Crossref: 110] [Cited by in F6Publishing: 107] [Article Influence: 10.0] [Reference Citation Analysis]
551 Rameshshanker R, Arebi N. Endoscopy in inflammatory bowel disease when and why. World J Gastrointest Endosc 2012; 4(6): 201-211 [PMID: 22720120 DOI: 10.4253/wjge.v4.i6.201] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
552 Koutroubakis IE, Ramos-Rivers C, Regueiro M, Koutroumpakis E, Click B, Schoen RE, Hashash JG, Schwartz M, Swoger J, Baidoo L, Barrie A, Dunn MA, Binion DG. Persistent or Recurrent Anemia Is Associated With Severe and Disabling Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2015;13:1760-6. [PMID: 25862987 DOI: 10.1016/j.cgh.2015.03.029] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 5.7] [Reference Citation Analysis]
553 Chateau T, Feakins R, Marchal-Bressenot A, Magro F, Danese S, Peyrin-Biroulet L. Histological Remission in Ulcerative Colitis: Under the Microscope Is the Cure.Am J Gastroenterol. 2020;115:179-189. [PMID: 31809296 DOI: 10.14309/ajg.0000000000000437] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]